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The slit diaphragm component podocin is the protein product of the NPHS2 gene, which 
is mutated in a subset of patients with autosomal recessive steroid-resistant Nephrotic 
Syndrome (SRNS) that manifests as early childhood onset of proteinuria, focal segmental 
glomerulosclerosis (FSGS) and fast progression to end-stage renal disease (ESRN). Most 
disease-causing mutations of podocin result in its incorrect intracellular trafficking leading 
to aberrant formation/function of the slit diaphragm complex. Among these, the most 
frequent mutation is R138Q (57.5%), which alters the intracellular trafficking of podocin 
to the plasma membrane (PM), leading to its retention in the endoplasmic reticulum (ER). 
Interestingly, the most frequent worldwide mutation (F508del) of the cystic fibrosis 
transmembrane conductance regulator (CFTR) is also retained in the ER. Our collaborators 
have shown that this is due to aberrant interaction of this mutant with cytokeratin 8 (K8). 
Disruption of this interaction leads to the correction of the F508del-CFTR processing 
defect leading to its expression at the plasma membrane.  
Standard in vitro techniques were used to understand the effects of R138Q mutation on 
podocin trafficking and biology and to characterize the nature of R138Q-Keratin 8 
interaction in podocin’s bona fide cell type, the kidney podocyte. Furthermore, a 
conditional podocin knock-in mouse carrying a R140Q mutation, the mouse analogue of 
human R138Q, was created using doxycycline-inducible Cre-recombinase technology that 
allows for the study of the effects of the mutation in postnatal life and represents an ideal 
model for pharmacological studies.  
In this study, a previously unknown mechanism for the intracellular retention of the R138Q 
podocin mutant was identified. First, I demonstrated that Keratin 8 may physically interact 
with the R138Q podocin, and that ablation of K8 expression using shRNA in human R138Q-
expressing cells led to the correct association of podocin with lipid raft microdomains at 
the plasma membrane and the recovery of the adhesive function of the mutant cells. 
Excitingly, interruption of this interaction in the R138Q podocin mutant podocytes with a 
small molecule compound also results in the correct targeting of the mutant protein to 
the plasma membrane and restores its function. The involvement of keratin 8 network in 
the misfolded protein response was further demonstrated in vivo, where a continuous 28-
days treatment with a small molecule compound prevented the development of 
proteinuria in the NPHS2flox/R140Q mice. Together, these results show that the disruption of 
the K8-R138Q interaction potentially using chaperone drugs already developed in the 
Cystic Fibrosis (CF) field may provide a novel therapeutic target for SRNS patients bearing 
the R138Q mutation. I have also identified a novel binding partner of podocin, and a new 
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Chapter 1: General Introduction 
1.1 The Kidney 
The (human) kidneys are a pair of bean-shaped filtering organs approximately 5 inches in 
length, located towards the posterior muscular wall of the abdominal cavity. The kidneys 
(Figure 1.1) process the plasma portion of blood and, in so doing, they perform several 
fundamental functions, including secreting hormones, such as calcitriol and 
erythropoietin [1], regulating blood pressure via renin production [2] and 
gluconeogenesis. The principal function of the kidneys, however, is the excretion of 
metabolic waste products, such as creatinine and urea, into the urine as soon as they are 
produced as a result of protein catabolism. This waste removal is achieved by filtering the 
blood, thus maintaining its water/ion balance, and is carried out by the nephrons. The 
typical adult human kidneys process approximately 180 litres of primary urine devoid of 
macromolecules per day at the filtration rate of 125 ml/min. 
 
 
Figure 1.1 A cross section of the human kidney. Unfiltered blood enters the human 
kidney via the renal artery and leaves via the renal vein once filtered. Urine containing the 
excess waste products and fluid is excreted from the kidney via the ureter. Image 




There are approximately 2 million nephrons present in each human kidney. Each nephron 
is composed of the renal corpuscle and a tubule (Figure 1.2) [4]. The renal corpuscle is the 
part of the nephron that forms cell and protein free filtrate from blood; more precisely a 
specialised bundle of capillaries called the glomerulus is responsible for this filtration 
process [5]. As filtrate made by the glomerulus leaves the renal corpuscle, it enters the 
proximal convoluted tubule, where substances, such as amino acids, glucose, albumin and 
LMWPs, are reabsorbed back into the bloodstream [4]. The filtrate then enters a long, U-
shaped duct called the loop of Henle, which aids the recovery of water and NaCl from the 
urine. Once the filtrate passes through the ascending limb of Henle, it reaches the distal 
convoluted tubule, which reabsorbs calcium and sodium and regulates the pH of urine [6]. 
Finally, the filtrate enters the collecting duct, which concentrates urine from the nephron. 
  
 
Figure 1.2 The Nephron. Filtrate made by the glomerulus leaves via the proximal 
convoluted tubule, onto the loop of Henle, the distal convoluted tubule and finally 
reaches the collecting duct. Image modified from [7]. 
1.2 The Glomerulus and its development  
As mentioned above, one of the central roles of the human kidney is to filter blood 
through primary urine production in the glomerulus [8]. The mammalian glomerulus is a 
highly complex vascular bed that serves as a filter, restricting the passage of cells and high 




molecules, sugars and electrolytes to pass though [9]. The glomerulus is composed of a 
capillary tuft surrounded by the Bowman’s capsule, which directs the filtered primary 
urine to the tubular system for further processing [10]. Abnormalities to the glomerulus 
at any stage of life ultimately lead to a severe disease, so proper development and 
maintenance of this structure is required.  
Renal development has been previously studied in various animal models, such as 
zebrafish and mice, which allowed the characterization of three distinct stages of the 
kidney’s differentiation ontogenetically. These are the pronephros, which mature into the 
mesonephros, which further develop into the metanephric kidney [11]. In comparison to 
the pronephros and mesonephros, the metanephric kidney represents a stable structure, 
and its development is defined by reciprocal crosstalk between the metanephric 
mesenchyme (MM) and the uretic bud (UB), leading to the formation of the renal vesicle 
around the 5th week of gestation in humans [12],[13] .The MM will further give rise to all 
proximal parts of the nephron, while the UB will branch into collecting ducts, renal calyces 
and the rest of the urinary tract system [14]. 
The inductive signals of the UB drive the condensation of the MM towards the renal 
vesicle, while also result in a mesenchymal-to-epithelial transition, thus marking the 
beginning of the future nephron development [15]. The comma-shaped bodies are 
formed after this initial condensation, which further undergo morphological changes to 
give rise to the S-shaped body, also known as the precursor structure of the glomerulus 
[15]. At this stage of the glomerular development three main components can be found: 
a layer of visceral epithelial cells, known as podocytes, a thin layer of Bowman’s capsule, 
and a capillary loop made of immature endothelial cells [9]. It remains unclear how the 
podocytes cover the outside of the capillary loop. However, what’s known is that at the 
beginning of this process, both the podocytes and the capillary endothelial cells develop 
their own basal lamina, which fuse with each other forming a thick basement membrane, 
called the glomerular basement membrane (GBM) [9]. The outcome of this fusion results 
in the podocytes and endothelial cells being brought into close proximity to each other, 
allowing podocytes to undergo a significant transformation [9]. During this 
transformation the podocytes gain some mesenchymal-like features, although remaining 
an epithelial cell, and start to lose their lateral cell attachments, except the ones at the 
basal membrane (Figure 1.3) [9]. At this point, podocytes almost completely enwrap the 




of each other, develop several large branch-like projections, from which many smaller 
foot processes extend and interdigitate with those of neighbouring podocytes to form slit 
diaphragms (discussed in detail below) [9]. 
 
Maturation of the glomerular capillaries begins with a single capillary loop composed of 
endothelial progenitors invading itself into the vascular cleft and requires primitive 
podocytes to produce angiogenic factors, such as VEGF-A [16]. As the development 
progresses, the capillary loop starts to divide into six to eight loops [17]. The endothelial 
cells of the capillaries gain a perforated-like appearance, such that now there are slit-like 
openings on either side of the GBM: the actual filtration slits between interdigitating foot 
processes of podocytes and holes through the endothelial cells themselves [9]. Following 
the endothelial cells, specialized smooth muscle cells, known as mesangial cells, also 
migrate through the vascular cleft, where they are suggested to help extend the capillary 
Figure 1.3 A model of the podocyte and foot process assembly. (A) Two immature 
columnar podocytes are attached along their lateral membranes. (B) Podocytes lose their 
lateral membrane attachments and begin to interdigitate at the basally attached regions. 
(C) Independent of each other, podocytes are still attached through their interdigitated 




loops into branches and respond to different physical stimuli [9]. The finding discussed in 
this section has led to the conclusion that the proper development and interaction of both 
podocytes and glomerular endothelial cells results in the formation of the glomerular 
filtration barrier (GFB).  
1.3 The Glomerular Filtration Barrier 
The glomerulus, being situated in the most proximal part of the nephron, acts as a key 
functional regulator for renal ultrafiltration [15]. The filter itself represents a three-
layered structure consisting of the intervening glomerular basement membrane (GBM), 
glomerular endothelial cells (GEnCs) and glomerular epithelial cells, known as podocytes, 
and lies between the glomerular vasculature and Bowman’s capsule (Figure 1.4) [18]. The 
filtration barrier serves as a selective sieve restricting the passage of macromolecules 
according to their size, charge and shape, while being freely permeable to water and small 
solutes in plasma. It’s believed that the flow of the glomerular filtrate takes an 
extracellular route, beginning from the innermost fenestrated endothelium, then across 
the GBM, and finally through the slit diaphragm of podocytes [10]. Diseases affecting 
either one or any of the layers result in the presence of high amounts of albumin in the 
urine, the condition known as proteinuria. Therefore, each of the three core layers has its 
own role in filtration specificity, which will be outlined in more detail below, and their 
physicochemical and signalling interplay is essential for maintenance of the GFB integrity 
in both health and disease [19].  
 
Figure 1.4 The Glomerular Filtration Barrier. Transmission electron microgram of a cross 
section of the GFB, which is composed of three main components: glomerular endothelial 




podocyte foot processes (P) that interdigitate creating the slit diaphragm (SD) (Layer 3). 
Adapted from Pavenstädt et al [20]. 
 
1.3.1 Layer 1: The Glomerular Endothelial Cells 
The glomerular vasculature is made of afferent and efferent arterioles, and the capillary 
tuft. Blood enters the glomerulus via the afferent arteriole and exits via the efferent one. 
Within the glomerulus, the afferent arteriole instantly divides into the glomerular tuft, 
which acts as a functional unit for blood filtration [21]. Unlike the afferent and efferent 
arterioles, the GEnCs monolayer lines the capillary side of the GFB and is the first point of 
contact of the plasma with the GFB. The glomerular capillaries show increased 
permeability to water and small solutes, when compared to most other capillary beds. 
This high hydraulic conductivity is partly due to the GEnC monolayer having a fenestrated 
appearance, caused by transcellular pores, known as fenestrae, that cover it [21]. The 
fenestrae themselves are 60-100 nm wide and cover around 20-50% of the glomerular 
capillary surface area, thus establishing glomerular capillaries as an essential part of the 
renal ultrafiltration (Figure 1.5A) [22]. 
The development of the GEnC monolayer has been widely studied in rodent models. The 
earliest GEnC emerge from mesenchyme, also known as angioblasts, drifting into the cleft 
of the glomerulus at the S-shaped body phase of development; these cells have cuboidal 
appearance and lack fenestrations [23]. During the capillary loop phase podocytes are 
observed on the adverse side of the maturing GBM, and the endothelial cells start to 
proliferate, where their cytoplasm narrows down before fenestration’s formation [24]. At 
this stage the fenestrations have diaphragms, which disappear as the glomerular 
endothelium progressively matures and as podocyte foot processes start to develop [24]. 
Therefore, it has been stated that the GEnC fenestration’s formation runs in parallel with 






Figure 1.5 The Glomerular Endothelial Cells. (A) Scanning electron micrograph of a highly 
fenestrated glomerular endothelium. Adapted from Kamba et al [25].(B) Transmission 
electron micrograph of the GFB, showing that the luminal side of the glomerular 
endothelium is covered by a fine layer of glycocalyx (G). Adapted from Rostgaard and 
Qvortrup [26].  
 
Due to the large size of the fenestrae in comparison to albumin for example, the idea that 
the GEnCs could play an essential role in protein filtration was contentious. However, 
recent studies have demonstrated that the glomerular endothelium does indeed take part 
in the barrier function because of its negatively charged surface [21]. The luminal side of 
the glomerular capillaries and the fenestral surface are covered by the glycocalyx, a thick 
(200-500 nm) layer as determined by electron microscopy (Figure 1.5B) [27]. The 
glycocalyx mainly consists of negatively charged glycoproteins and proteoglycans [22]. 
Furthermore, absorbed plasma components within the glycocalyx form a broader layer 
called the endothelial surface layer (ESL) [28]. The strong negative charge of the surface 
layer causes fenestrae to become narrower and more restrictive [21]. Enzymatic digestion 
of various ESL elements caused increased albumin permeability across the endothelium 
together with decreased ESL depth and loss of charge on the glomerular endothelial 
surface layer [29]. Analogously, the importance of the ESL was demonstrated in mice 
models, where adriamycin perfusion also resulted in the glomerular ESL shrinkage, thus 
supporting the theory that GEnCs contribute to the charge-selectivity of the GFB [30].  
The proteoglycans are critical for the glycocalyx formation, and consist of a core protein 
and covalently attached glycosaminoglycan (GAG) side chains [31]. Five types of GAG side 




sulphate, keratan sulphate and hyaluronic acid [32]. Interestingly, hyaluronic acid is the 
only nonsulphated, uncharged side chain linked to cell surface proteins instead of any 
core proteins [32]. GEnCs are considered to produce the most abundant proteoglycan, 
known as heparan sulfate [33]. Heparanase III and human heparanase are enzymes that 
specifically cleave heparan sulphate, and have been reported to increase the albumin 
permeability across the monolayer, whilst resulting in no change in trans-endothelial 
electrical resistance [31]. Interestingly, neuraminidase treatment led to the removal of 
almost all of the glycocalyx, which consequently decreased trans-endothelial electrical 
resistance and elevated albumin influx in vitro [31]. Taken together, these findings suggest 
that the human endothelial cell glycocalyx is involved in the size and charge restriction of 
protein passage, which might explain why patients with preeclampsia, a disease 
associated with a glomerular lesion known as endotheliosis, present with protein in the 
urine due to their loss of the endothelial cell glycocalyx [34],[35]. 
1.3.2 Layer 2: The Glomerular Basement Membrane  
After passing through the first layer of the GFB, the filtrate next contacts the GBM - an 
essential element of the GFB derived from the fusion of the individual basal membranes 
of both podocytes and GEnCs during glomerulogenesis. Similar to other basement 
membranes, the preeminent components of the GBM are type IV collagen, nidogen, 
laminin and heparan sulfate proteoglycans [36]. However, past studies have 
demonstrated that the GBM has its own specific protein isoforms, which are essential for 
correct glomerular development and function. In particular, what distinguishes the GBM 
is the expression of the following isoforms - laminin α5β2γ1, collagen IV α3α4α5 and agrin 
[37]. These specific protein isoforms are able to create an interwoven meshwork of 300 
to 350 nm in thickness believed to play a role in both size- and charge- selective properties 
of the GFB [38]. Despite the fact that the composition of the GBM has been studied for a 
while, there is still a debate about its role as the primary filter compared to that of 
podocytes and endothelial cells.  
Laminin characterizes a family of evolutionary conserved glycoproteins that are able to 
interact with each other in a non-random manner to create at least 15 various αβγ 
heterotrimers, which are produced by different cell types and secreted into the 
extracellular space [39]. Interestingly, the extracellular space is where the laminin 
polymerization occurs that is essential for the initiation of basement membrane 




(α5β2γ1) is the main laminin present in the mature GBM secreted by both endothelial 
cells and podocytes. As glomeruli progress through their development, laminins (αβγ 
heterotrimers) undergo developmental transitions within the GBM [40]. Specifically, 
laminin 111 (α1β1γ1) is mainly present in the earliest epithelial cells of the nephron, and 
its expression then shifts to laminin 511 (α5β1γ1) and finally to laminin 521 (α5β2γ1) upon 
further development [41]. It has been shown that mutations in laminin prevent these 
developmental transitions from occurring revealing their significance. Laminin β2 chain 
deficient mice, for example, show massive proteinuria due to GBM dysfunction and die in 
the perinatal stage [42], while in humans mutations in β2 gene lead to Pierson’s syndrome 
[22].  
Similar to all collagens, collagens type IV are also secreted as heterotrimers consisting of 
three α chains whose sequence contains multiple Gly-X-Y repeats, which are believed to 
add the flexibility to the collagen network [43]. Analogous to laminin transitions, GBM 
type IV collagen also undergoes developmental transitions during glomerulogenesis. At 
the early stages of the development, collagen IV α1 and α2 chains, secreted by both 
podocytes and endothelial cells, are mainly expressed [44]. Upon maturation of the 
glomerulus, podocytes start to synthesize the α3α4α5 trimers, which then polymerize to 
form the triple-helical type IV collagen network of the mature GBM [45]. This highly 
organized type IV collagen network gives flexile strength and support to the capillary wall. 
This explains why mutations in the genes encoding any one of the type IV collagen α3, α4, 
or α5 chains can lead to severe abnormalities in the GBM. Heterozygous null mutations in 
collagen IV α3 or α4, for example, cause benign familial hematuria, also well known as 
thin basement membrane disease, while in the homozygous state these mutations result 
in autosomal recessive Alport syndrome characterized by progressive renal failure [37].  
Concerning the other two components of the GBM, nidogens and heparan sulfate 
proteoglycans, such as agrin, little is known about their developmental transitions during 
glomerulogenesis. Both nidogen 1 and nidogen-2 are found in the mature GBM although 
interestingly lack of their expression in mice has no significant influence on the glomerular  
filtration [39]. Similarly, ablation of agrin in the GBM results in no dramatic defects on 
glomerular permeability, even though it causes a drastic anionic charge reduction [46]. 
Overall, it has been suggested that the GBM plays a small part in charge-selectivity, but it 
acts primarily as domain for the endothelial glycocalyx, as the proteoglycans are able to 




1.3.3 Layer 3: The Podocytes 
The final layer of the GFB is composed of podocytes, also known as glomerular visceral 
epithelial cells, which are terminally differentiated, highly specialized epithelial cells with 
a complex and unique 3D cellular cytoarchitecture found on the urinary side of the GFB 
[19]. Glomerular podocytes are endowed with an epithelial polyanion cell surface coat, 
which is mainly comprised of podocalyxin, a heavy glycosylated protein [48]. The 
podocyte is able to synthesize podocalyxin itself inserting it into the apical side of the 
plasma membrane, where it is believed to maintain the filtration slit opening [49]. It has 
been demonstrated that puromycin aminonucleoside-treated (PAN) rats present with 
heavy proteinuria due to the reduced sialylation of podocalyxin, thereby highlighting the 
importance of the negatively charged surface of podocytes [50]. Healthy fully 
differentiated podocytes have voluminous cell bodies, which resemble the body shape of 
an octopus, with numerous projections subdivided into the larger major processes and 
the finer foot processes (Figure 1.6) [21]. Typically, the podocyte’s cell body protrudes 5 
to 10 primary processes, which are further projected into multiple foot processes [51]. 
Recently, using a block-face scanning electron microscopy, Ichimura et al. demonstrated 
that the foot processes were projected from the podocyte’s cell body via ridge-like 
prominences, suggesting that the podocytes are anchored to the GBM [52]. More 
precisely, these prominences provide an adhesion platform for the direct anchorage of 
the cell body and primary process to the GBM, while also serving as linkers to connect the 





Figure 1.6 Conventional scanning electron micrograph of podocytes enwrapping a 
glomerular capillary. Each podocyte is individually coloured. Interdigitating foot 
processes can be observed extending from each primary process. (CB=cell body, 
P=primary process). Adapted from Ichimura et al [52]. 
 
There is a close link between podocyte morphology and the actin cytoskeleton. The two 
types of processes in podocytes are defined by their well-developed internal cytoskeletal 
systems, which play an essential role in sustaining cell structure and the maintenance of 
the processes [53]. The core cytoskeletal components of the major processes are 
microtubules and intermediate filaments, such as vimentin, whereas actin-rich filaments 
dominate in the foot processes [53]. Therefore, this might help to explain why only the 
foot processes are affected in glomerular disease. There are two different actin-based 
structures found in foot processes during development and after injury, which are 
lamellipodia and filopodia that are responsible for their movement and extension [54]. In 
addition, focal adhesion complexes are involved in movement, while also allow for the 
tethering of the foot processes to the GBM, thus preventing their detachment within the 
glomerular structure [54]. Podocyte movement occurs, when the foot processes exhibit 
opposing forces that pull on the cell body by extending the protrusions; thereby, each 
movement results in the re-establishing of the new adhesion point once the lamellipodia 




within the podocyte foot process; an example is the actin-based motor protein, Myoc1, 
which transports the podocyte protein NEPH1 to the podocyte cell membrane [56]. 
The podocyte cell bodies enwrap the outer surface of the glomerular capillaries by 
extending foot processes that interdigitate with those of neighbouring podocytes forming 
specialized cell-to-cell junctions called slit diaphragms [20]. The slit diaphragm contains 
proteins, such as zona occludens-1 [57] and P-cadherin, which are commonly found in 
tight and adherens junctions respectively, however it lacks E-cadherin and has a porous 
structure [58]. The slit diaphragm represents a dynamic multiprotein apparatus that 
consists of integral membrane proteins, ion channels, scaffolding and signalling proteins 
(Figure 1.7). This multiprotein complex must accomplish essential tasks, such as acting as 
a filter as well as anchoring the podocyte to the GBM. It has become the main focus of 
research since the discovery of single-gene mutation in slit diaphragm proteins that were 
found to be responsible for the development of Nephrotic Syndrome (NS) (discussed in 
more detail below). The first such protein discovered was the transmembrane protein 
nephrin, a member of the immunoglobulin superfamily, which has been identified at the 
podocyte slit diaphragm (discussed in further detail below) [59]. Its homophilic interaction 
with nephrin from an adjacent podocyte is considered to be the “pore” of the slit 
diaphragm [60]. Nephrin’s intracellular domain is able to interact with proteins, such as 
podocin, to facilitate actin polymerization into specific arrangements, which is essential 
for foot process architecture [60]. This is supported by the fact that single-gene mutations 
in actin-binding proteins, such as α-actinin-4 and inverted formin 2, result in hereditary 
nephrotic syndrome, in which foot processes show abnormalities [61],[62]. Being such a 
specialized complex, the slit diaphragm has recently been appreciated to function as a 
signalling platform controlling podocyte cell survival, endocytosis, and polarity, along with 
actin cytoskeleton organization [63]. Thus, gene defects in a number of components of 





Figure 1.7 A cartoon illustration of the main molecular elements of the podocyte slit 
diaphragm. Reproduced from Grahammer et al [64]. 
 
The podocyte slit diaphragm itself acts as a final barrier in the GFB ultrafiltration, which 
means that the occurrences of foot process effacement (FPE) are problematic for GFB 
permeability. Disruption of foot process architecture results in FPE, a proteinuria-
correlated process activated by podocytes in response to the injurious stimuli [65]. 
Podocyte effacement is, indeed, a very complex and dynamic process involving various 
phosphorylation-driven and signalling based events [54]. The actual term FPE describes 
the physical loss of the interdigitating pattern of foot processes of neighbouring 
podocytes, where the two distinct phases are distinguished. During the first stage, foot 
processes retract and change their shape into irregular broadened projections, causing 
slit diaphragms being either lost or displaced [66]. The second phase, also known as the 
complete stage of FPE, describes the formation of flattened disk-like projections spread 
along the GBM, which eventually merge with the cell bodies [67] Interestingly, FPE seems 
to be reversible and is a consequence of active actin filament reorganization subsequent 
to intracellular signals [68]. The best example of reversibility of FPE arises from patients 
with minimal change disease upon treatment, while in contrast focal segmental 
glomerulosclerosis (FSGS) patients present with more severe and irreversible FPE [19]. 




placing them in the centre of thinking with regard to the direct link to genetic forms of 
NS. 
1.4 Nephrotic Syndrome and genes identified 
Dysfunction of the glomerular filtration barrier, leading to extensive leakage of plasma 
proteins into the urine and podocyte foot processes effacement observed by electron 
microscopy, is detected in many inherited and acquired nephropathies [69]. The clinical 
indication is nephrotic syndrome (NS), described as a triad of heavy proteinuria (>40 
mg/m2/hr), oedema and hypoalbuminaemia (<3.0 g/dL), and which often results in end-
stage renal disease (ESRD), accounting for 15% of the cases in the European population 
[70]. Even though NS is linked to various types of renal disease, the most common form 
(90%) identified in children is idiopathic NS, which progresses in the absence of any clinical 
features of primary extrarenal disorder [70]. In rare cases, childhood NS can be caused by 
the systemic inflammation or autoimmune disorders or can be due to infections, toxins , 
drugs or other inherited renal diseases [71].  
Clinically, NS can be classified into two groups by the response to steroid therapy: steroid-
sensitive NS (SSNS) and steroid-resistant NS (SRNS). Most patients with idiopathic NS 
initially respond well to steroids and enter the remission stage with a good renal 
prognosis; however, around 90% of these patients will relapse, with another half of those 
becoming steroid-dependent [70]. The remaining 10% are recognized to have SRNS. 
However, this fails to explain why some patients who originally respond to steroid 
treatment later become resistant. As mentioned before, NS is considered to be the most 
prevalent glomerular disease of childhood, with an incidence of around 2 in 100,000 
children [72]. Approximately 20% of children will be steroid resistant, with a further 60% 
of these cases presenting with focal segmental glomerulosclerosis (FSGS), indicated by 
biopsy [73]. FSGS is described as scarring of the glomerulus that includes several distinct 
changes, where only a segment of the glomerulus and some, but not all, glomeruli are 
affected [74]. Progression to ESRD is closely correlated with the development of FSGS. 
Therefore, because most cases of genetic NS are clinically steroid-resistant with 
pathologically prevalent FSGS, genetic NS is hard to treat, has poor renal prognosis and 
often results in ESRD. 
The majority of the SRNS genetic forms show structural alterations in the glomerulus or, 




has revealed the podocyte as a key player in regulating glomerular filtration, whose 
structure and function are essential in the maintenance of the slit diaphragm membrane 
[73]. The ongoing identification of genetic defects in podocyte-specific genes has 
undoubtably expanded our understanding of pathophysiology in genetic NS in regard to 
clinical onset, diagnosis, therapeutic and prognostic approaches [75]. To date, around 75 
genes including those encoding nephrin, transient receptor potential canonical channel-6 
(TRPC6), CD2AP, α-actinin-4 and podocin, have been reported to cause NS, and yet more 
remain to be identified (Table 1.1). Proteins affected by genetic mutations have been 
found to be expressed at various intracellular locations within the podocyte, such as cell 
membrane, mitochondria, nucleus and cytoskeleton. The significance of several of them, 
including nephrin, CD2AP and podocin, which participate in the slit diaphragm assembly, 
has been shown by the presence of heavy proteinuria, when they are mutated [76]. The 
major ones will be discussed in further detail below. 
  
NPHS1 AR CNS/NS 
NPHS2 AR CNS, NS – childhood and adult onset 
CD2AP ? Early-onset NS, HIV nephropathy 
TRPC6 AD Adult onset NS 
NUCLEAR PROTEINS 
WT1 Sporadic; AD Adult onset NS, Denys–Drash and Frasier 
Syndromes 
LMX1B AR Nail–Patella Syndrome/NS only 
PAX2 AD Adult onset NS 
ACTIN CYTOSKELETON AND SIGNALING 
ACTN4 AD Adult onset NS 
INF2 AD Familial/sporadic NS; Charcot-Marie-Tooth 
SYNPO ? Adult onset NS 
APOL1 Complex; AR Adult onset NS 
MYO1E AR Early or adult onset NS 
MITOCHONDRIAL 
COQ2 AR Mitochondrial disease/isolated nephropathy 
COQ6 AR NS with sensorineural deafness 
ZMPSTE24 AR Mandibuloacral dysplasia with NS 
GBM 
LMNA AD Familial partial lipodystrophy + NS 




COL4A4 AR Alport’s disease 
COL4A5 X-linked Alport’s disease 




Recent advances in the study of genetic diseases with malfunction of the glomerular 
filtration barrier provide useful models to explain the physiological mechanisms whereby 
such disorders occur. One of the most serious such conditions is congenital NS of the 
Finnish type (CNF), caused by mutations in NPHS1 gene encoding nephrin, the first 
podocyte protein discovered [76]. These mutations result in the complete deletion or 
partial truncation of the protein, therefore, revealing its significance in the maintenance 
of the GFB [78]. CNF is an autosomal-recessive disorder that progresses itself in utero and 
results in massive proteinuria at birth or shortly after it [78]. Although the disease is 
detected in the population worldwide, it is highly frequent in Finland with an incidence of 
1:10,000 birth [79]. In most cases, CNF causes death at the neonatal stage, however, in 
early childhood it can be treated by dialysis and correct nutritional support followed by 
kidney transplantation [80]. Originally CNF was considered as a GBM disease, however no 
mutated genes coding for fundamental elements of the basement membranes were 
identified. Using the positional cloning approach, Kestilä et al. found a novel gene located 
in the 150 kb region of chromosome 19, which was defective in the majority of CNF 
patients studied, and called it NPHS1 [78].  
Nephrin, the gene product, is a 1241-residue putative transmembrane protein consisting 
of a short intracellular domain, an extracellular domain containing eight IgG-like motifs, 
and one proximal fibronectin type III-like motif (Figure 1.8A) [81]. Two cysteine residues 
linked by a disulphide bridge are present in each IgG-like motif, and these motifs in 
consequence are able to adopt a globular shape [81]. These IgG-like motifs are known as 
type C2 and identified in proteins involved in cell-matrix or cell-cell interactions [81]. 
Therefore, nephrin belongs to the Ig superfamily of cell adhesion molecules, and is 
exclusively localized to the podocyte slit diaphragm [59]. Based on the domain structure 
and specific location, it has been stated that nephrin molecules assemble in the slit 
diaphragm to form the porous substructure, with pores the size of albumin or smaller 




seen in a mouse model that presented massive protein leakage, foot processes 
effacement and absence of slit diaphragms, when the NPHS1 gene was inactivated [82]. 
 
Figure 1.8 Structure and interactions of nephrin. (A) Nephrin’s structure consisting of a 
C-terminal intracellular domain, followed by a single transmembrane domain, and a N-
terminal extracellular domain made of one fibronectin type III-like motif and eight IgG-
like motifs. (B) Nephrin molecules from adjacent podocytes interact in the middle of the 
slit diaphragm through homophilic interactions to form the porous substructure. (C) The 
extracellular domain of nephrin is also believed to interact with shorter Neph molecules, 
thus maintaining the slit diaphragm structure. Adapted from Patrakka and Tryggvason 
[81]. 
 
The extracellular domain of nephrin has ten potential N-glycosylation sites, nine of which 
indeed undergo N-linked glycosylation, which is essential for the correct folding and 
trafficking of nephrin to the plasma membrane [83]. Furthermore, the extracellular 
domain of human nephrin interacts with the recently discovered Neph family of proteins, 
and hence, extracellularly nephrin is believed to be involved in maintaining the slit 
diaphragm ultrastructure. In fact, this interaction has been previously seen in vivo 
between Neph and nephrin homologs in Drosophila melanogaster, and was shown to be 




Neph3) are transmembrane proteins with a shorter extracellular domains consisting of 
five IgG-like motifs that are structurally related to nephrin [81]. These proteins are found 
in a variety of tissues, and in the glomerulus Neph 1 and Neph 2 are specifically localized 
to the slit diaphragm [85]. The interactions of nephrin and Neph 1 are highlighted to be 
essential for maintenance of glomerular filter integrity, as injection of appropriate doses 
of both anti-nephrin and anti-Neph1 antibodies into rats results in proteinuria [86]. The 
function of Neph 2 at the glomerular slit diaphragm remains to be identified. 
Nephrin’s intracellular domain consists of 154 amino acids, including several tyrosine 
residues that can become phosphorylated, suggesting that nephrin is involved in 
intracellular signalling [81]. Both in vitro and in vivo experiments have demonstrated that 
nephrin is directly tyrosine-phosphorylated by Fyn, the Src family kinase member [87]. 
This phosphorylation activates the PI3K/AKT pathway, which protects podocytes from 
apoptosis. Nephrin tyrosine phosphorylation also leads to the recruitment of the SH2-SH3 
domain-containing Nck family of adaptor proteins and regulates actin cytoskeleton 
dynamics [88]. 
1.4.2 CD2-associated protein (CD2AP) 
CD2AP is an 80 kDa multidomain protein consisting of three Src homology 3 (SH3) domains 
at the N-terminus, followed by a proline-rich region, a potential actin binding domain and 
a coiled-coil domain at the extreme C-terminus, suggesting that it functions as an adaptor 
protein (Figure 1.9) [89]. It was originally described as a protein involved in T-cell 
activation and found to be expressed in all tissue apart from the brain. In the kidney, 
where the ultrafiltration takes place, CD2AP was shown to play a crucial role. In fact, in 
glomerular podocytes CD2AP interacts with nephrin via its C-terminal domain and 
localizes to the slit diaphragm as seen by immunoelectron microscopy [90]. Loss of CD2AP 
expression in the glomerulus initially results in epithelial cell injury, which further leads to 
mesangial matrix expansion, glomerulosclerosis and global foot process effacement [91]. 
Accordingly, mice lacking CD2AP present with severe NS and die of renal failure soon after 
birth, while heterozygous mice develop a glomerular disease at 9 months with lesions 
mimicking those of human FSGS [92]. The renal phenotype of these mice was completely 
rescued by the expression of CD2AP in podocytes, therefore, highlighting the important 





Figure 1.9 Schematic representation of the CD2AP protein. Three SH3 domains are 
located at the N- terminus, followed by a proline-rich region. A coiled-coil domain and an 
actin capping protein (CP) binding motif are found at the C-terminus. Reproduced from 
[94]  
CD2AP is an intracellular protein that acts as a linker protein, which is involved in podocyte 
slit diaphragm assembly, different signalling pathways, actin cytoskeleton regulation and 
endocytosis [89]. Like nephrin, CD2AP is able to bind an intermediary protein, p85, via its 
N-terminal domain, therefore recruiting PI3K to the plasma membrane and initiating the 
nephrin-induced PI3K/AKT signalling pathway to have antiapoptotic effects in podocytes 
[95]. Moreover, in vitro experiments have demonstrated that the interaction between 
podocin, nephrin and CD2AP stimulates AKT and, in turn, regulates gene expression, actin 
cytoskeleton remodelling and apoptosis. Podocytes lacking CD2AP show increased 
apoptosis and defects in the CD2AP gene lead to proteinuria in mice, suggesting that 
CD2AP is a crucial component of the glomerular filtration barrier [91]. 
1.4.3 TRPC6 
Another important component of the glomerular slit diaphragm is the ion-channel TRPC6, 
a member of the large transient receptor potential (TRP) superfamily, which has been 
shown to play a pathogenic role, when mutated [96]. This superfamily is best known for 
their ability to mediate Ca2+ release and function as cellular detectors aiding osmolar and 
fluid flow sensing [97]. Therefore, the discovery of TRPC6 in podocyte foot processes 
suggests that Ca2+ signalling is required for healthy podocyte structure and function and 
as a result for the maintenance of a proper GFB.  
The mammalian TRP superfamily is made up of proteins with the highest homology to 
Drosophila TRP [98]. All TRP channels consist of six transmembrane domains that 
assemble as tetramers to form cation-permeable pores, and have been grouped into 
seven subfamilies in mice and six in humans, including the classical or canonical TRPC 
proteins, according to the amino acid sequence homology [98]. In general, they are 
ubiquitously expressed, and have diverse functions. TRP channels are composed of an N-
terminal cytoplasmic domain containing several ankyrin repeats (four in the case of 




forming region is located between segments 5 and 6 and a C-terminal cytoplasmic domain 
that has a TRP sequence (Figure 1.10) [99]. The 25-residue TRP sequence is highly 
conserved among all the TRP channels and comprises a motif called TRP box 1, followed 
by a proline-rich region known as TRP box 2 [99]. Coiled-coil sequences have been 
identified in both the amino- and carboxy- domains with an additional calmodulin and IP3 
receptor-binding domain known as CIRB region found in the COOH-terminal [96],[99]. 
Coiled-coil sequences, ankyrin repeats and proline-rich regions are believed to be 
essential for protein-protein interactions, while the domain structure opens a window for 
unique associations with other proteins [99] 
   
Figure 1.10 Schematic representation of the TRPC6 domain structure. Human disease-
causing mutations known to cause FSGS are found in both the amino- and carboxy- 
domains and indicated in boxes. Reproduced from Dryer and Reiser [99] 
There is around 65% of identity between TRPC4 and TRPC5, while TRPC1 and TRPC2 are 
almost unique [100]. TRPC6, a member of the canonical TRPC subfamily, is a receptor-
operated channel leading to the influx of calcium [96]. Although all TRPC subfamily 
members respond to phospholipase C (PLC) signals, TRPC3, 6 and 7 share around 70-80% 
identity at the amino acid level and have been grouped together due to the ability to 




Winn et al. were the first to identify a point mutation in the TRPC6 gene in a large family 
with autosomal dominant FSGS [101]. To date, there are 10 disease-causing mutation 
identified in human TRPC6 gene shown in Figure 1.10, some of which are gain-of-function 
mutations resulting in an elevated influx of Ca2+ into the cells, while the others lead to 
longer opening channel function, once activated [101]. Interestingly, patients with 
mutations in the TRPC6 gene present with FSGS with no other pathological phenotype 
observed, even though TRPC6 is widely expressed in variety of tissues. One possible 
explanation for this is that TRPC6 plays an essential role in the assembly of the filtration 
slit or the structure is highly susceptible to even slight changes in Ca2+ dynamics [99].  
This prompted further research to study the renal expression of TRPC6. TRPC6 is broadly 
expressed throughout the kidney in tubules and glomeruli. However, most of the TRPC6 
expression is confined to podocytes, where it localizes within both major processes and 
foot processes, and to the slit diaphragm [102]. Interestingly, TRPC6 expression was also 
detected in glomerular endothelial cells [102]. The precise role of TRPC6 in the podocyte 
is still unknown, but it is thought to be involved in mechanosensory events at the slit 
diaphragm or in signalling to the actin cytoskeleton via calcium-dependent pathways 
[103]. TRPC6 channels can interact with podocin and nephrin at least in cultured 
podocytes, and these interactions are likely to be key for the maintenance of these 
channels at the filtration slits [104]. Podocin was demonstrated to control the activity of 
TRPC6 in a cholesterol-dependent fashion, where podocin interacts with and alters the 
lipid microenvironment around the channel, thus leading to its activation in response to 
deformation of the plasma membrane [105], [99]. Moreover, TRPC6 was shown to 
interact with nephrin at or near the slit diaphragm, where this interaction is believed to 
regulate the gating and trafficking function of the channel [88]. This interaction is able to 
sense mechanical stimuli, which further activates Ca2+ signalling cascades leading to 
alterations in cytoskeletal dynamics of podocytes [99]. For example, nephrin ectodomain 
engagement leads to local activation of Src kinases, such as Fyn, which in turn results in 
tyrosine phosphorylation of the TRPC6 channel and an increase in its activity, thus altering 
the cytoskeletal dynamics [88], [106]. Furthermore, it has been shown that 
overexpression of TRPC6 in cultured podocytes results in the loss of actin stress fibres, 
leading to rearrangement of the podocyte actin cytoskeleton [107]. A similar outcome 
was observed in neonatal nephrin knockout mice [102]. Altogether, there is some 
evidence to propose that TRPC6 channel activity at the slit diaphragm of the podocyte is 




1.4.4 Inverted formin 2 (INF2) 
While mutations in the TRPC6 gene are best characterized as causes of familial FSGS, in 
recent years more candidate genes, such as INF2, have been reported. The INF2 gene 
encodes protein INF2, a member of the formin family of actin-regulatory proteins. INF2 is 
highly expressed in the kidney as well as in glomerular podocytes, which are believed to 
initiate the majority of forms of FSGS.  
Similar to other formin family members, INF2 is composed of an N-terminal diaphanous 
inhibitory domain (DID), and a C-terminal diaphanous autoregulatory domain (DAD) and 
formin homology domains (FH1 and FH2) [108]. Additionally, the N-terminal part 
generally has a regulatory function and includes an overlapping Rho binding domain, 
while the C-terminal DAD domain can also act as a monomeric G-actin binding Wiskott-
Aldrich syndrome homology region 2, known as WH2 domain [109]. The mammalian 
formin INF2 has a unique biochemical feature, it is able to accelerate polymerisation and 
depolymerisation of actin in vitro, and it displays ER and cytoplasmic localizations in 
podocytes [108]. This dual catalytic activity is dependent on both the FH2 and WH2 acting 
in pair [108]. Mutations in the INF2 gene were first identified by Brown et al. in 11 
unrelated families with FSGS [62]. The described disease-causing INF2 mutations were all 
found to be located within the DID, an autoinhibitory domain, and they all caused non-
conservative substitutions in highly conserved amino acid residues. The DID domain binds 
the DAD domain of INF2, which results in autoinhibition of INF2-mediated actin 
depolymerisation [108]. Interestingly, FSGS-associated mutations, such as E184K and 
R218Q, in the DID domain were shown to alter INF2 and F-actin localization in transfected 
podocytes, while they didn’t prevent INF2-mediated accumulation of actin filaments [62]. 
The finding that mutations in the podocyte-specific formin INF2 cause FSGS demonstrates 
that the precise regulation of actin polymerisation is essential for proper podocyte 
function.  
1.4.5 Podocin 
Podocin is the protein product of the NPHS2 gene that is mutated in a subset of patients 
with autosomal recessive SRNS, which manifests as early childhood onset of proteinuria, 
fast progression to ESRN and FSGS [69]. Podocin is a 42 kDa podocyte specific integral 
membrane protein, and is a member of the stomatin family of proteins [69]. Using the 




chromosome 1q25-q31 and specifically expressed in the podocytes of developing and 
mature glomeruli [69]. Using in situ hybridization and immunohistochemistry methods, 
the expression profile of podocin has been studied both during human embryogenesis 
and kidney maturation, and in the podocytes [110]. Podocin was initially detected in 
human embryos at 5 weeks of gestation, which represent the earliest developmental 
phase studied [110]. The NPHS2 transcript was not found in any embryonic structures 
apart from the mesonephros, or more specifically it was expressed in the mesonephric 
future podocytes from the S-shaped body and in the presumptive podocytes of 
metanephric kidneys at a later stage [110]. Interestingly, podocin protein was only 
detected much later than the transcript. Podocin expression is elevated throughout 
glomerular development and remains high in podocytes of mature kidneys [110]. 
In podocytes, podocin is exclusively localized to the slit diaphragm, where it is involved in 
mechanotransduction events [104]. This crucial localization of podocin to the slit 
diaphragm is underscored by the fact that mice lacking podocin present with massive 
proteinuria, foot process effacement and absence of slit diaphragms [111]. Similar to all 
stomatin-like proteins, podocin is an integral protein of 383 amino acids consisting of an 
N-terminal domain, a short membrane domain and a C-terminal domain. Podocin has a 
unique topology with a single membrane domain forming a hairpin-like structure due to 
both the N- and C-terminal tails facing the cytoplasmic side of the slit diaphragm (Figure 
1.11) [112]. It also has a single hydrophobic domain, which embeds podocin into the inner 
leaflet of the lipid bilayer, and the prohibitin homology (PHB) domain that facilitates 
podocin binding to cholesterol in the PM and acts as a lipid recognition motif [105]. This 
binding results in cholesterol being recruited to the TRPC6 ion channel complex at the slit 
diaphragm, which, in turn, suggests that podocin binds and mediates TRPC6 
mechanosensory activity [103]. It has been demonstrated that podocin reduces 
mechanosensitivity of TRPC6 channels, so a failure of podocin to function correctly leads 
to hyperactivation of the TRPC6 channels at the slit diaphragm [113]. Therefore, 
mutations in genes encoding either podocin or TRPC6 could lead to severe glomerular 
diseases due to possible Ca 2+ overflow. Interestingly, podocin oligomerises into clusters, 
and nephrin molecules assemble at the slit diaphragm, where CD2AP acts as an adapter 
to connect the entire structure. The presence of the intact podocin at the slit diaphragm 
is essential for the recruitment of nephrin to the plasma membrane and for podocyte 






Figure 1.11 Schematic representation of membrane orientation of podocin. A single 
membrane domain forms a hairpin-like structure with both the N- and C-terminal tails 
facing the cytoplasmic side of the slit diaphragm. Podocin also contains a single 
hydrophobic domain and PHB domain. Adapted from Relle et al [115]. 
 
Multiple experimental studies show that podocin in its oligomeric form localizes to lipid 
raft microdomains in the slit diaphragm, where it recruits and colocalizes with nephrin. As 
mentioned previously, the slit diaphragm of podocytes is essential for the correct function 
of the GFB and is assembled in lipid rafts. These are highly dynamic specialized plasma 
membrane microdomains 10-200 nm in diameter enriched in glycosphingolipids, 
cholesterol and a number of signal transduction molecules, which are found in all 
eukaryotic cells (Figure 1.12) [116]. In comparison with the rest of the plasma membrane, 
there is 5-8-fold increase in cholesterol in lipid rafts, which is able to interact with 
glycosphingolipids via its hydrophobic side chains [117]. Therefore, having such a unique 
lipid composition, rafts have been suggested to function in many cellular processes, such 






Figure 1.12 Lipid rafts structure in the slit diaphragm. Podocin contains PHB domain that 
allows binding to cholesterol leading to the assembly of multiprotein complexes, such as 
between podocin, nephrin and TRPC6. Different lipids are highlighted in various shades of 
orange. Reproduced from Fornoni et al [118]. 
 
Lipid raft targeting of nephrin enhances its signalling activity from the slit diaphragm, 
which results in regulation of the podocyte actin cytoskeleton and glomerular 
permselectivity. Thus, it has been suggested that disease-causing podocin mutants might 
still colocalize with nephrin, but fail to target it to lipid rafts either because they cannot 
be intracellularly trafficked to the PM or they get to the PM, but are not recruited into 
rafts [119]. Apart from strong functional interaction between podocin and nephrin, 
podocin also binds CD2AP and TRPC6 via its C-terminus, demonstrating an important link 
between the slit diaphragm and the actin cytoskeleton [120]. Indeed, the complex formed 
allows for the attachment of the slit diaphragm to the actin filaments, therefore 
embedding the complex into the lateral part of the podocytic plasma membrane [121]. 
Taken together, podocin serves as a scaffolding protein involved in the organization of the 
SD complex and the mediation of its filtration function [122].  
1.4.5.1 Disease-causing podocin mutation R138Q 
Nowadays, genetic causes of SRNS are being progressively acknowledged. Mutations in 
the NPHS2 gene were first reported in children with autosomal-recessive SRNS and FSGS, 
followed by sporadic childhood and adult-onset SRNS cases. As stated before, mutations 
in podocin result in the dysfunction of the GFB with the variable age of onset and FSGS 




heterozygous mutations usually develop SRNS before 6 years of age that in the majority 
of paediatric cases rapidly progresses to ESRD with an extremely low frequency of 
recurrence after renal transplantation [120]. Late-onset patients are considered to be 
over 18 years of age and found to inherit a mutation and a non-neutral polymorphism, 
meaning that a variant is relatively common and doesn’t cause a disease until in a 
combination with a certain mutation  [123]. Interestingly, both N- and C-terminal 
cytoplasmic tails of the podocin may be affected by the mutations, which include loss-of-
function mutations, along with missense changes [124]. 
Indeed, missense mutations appear to represent the largest group of NPHS2 mutations 
accounting for 42 % of a total of the 126 mutations of NPHS2 reported to date [120]. The 
most frequent mutation identified in 42 of 73 families with two pathogenic mutations is 
the p.R138Q (c.413G>A) mutation in exon 3 [125]. Paediatric patients carrying truncating 
mutations (nonsense or frameshift), or homozygous p.R138Q, present with a severe, 
early-onset from of SRNS, which is found in 98.2% of cases studied [125]. The replacement 
of arginine residue at position 138, which is highly conserved amongst the stomatin-like 
family of proteins and is crucial for podocin function, with glutamine results in podocin 
with the R138Q mutation [69]. Functional data have shown that this protein is retained in 
the endoplasmic reticulum (ER) and loses its ability to target nephrin to lipid raft 
microdomains, therefore augmenting its signalling [119]. By screening the patient 
database, Roselli et al. found that patients with mutations resulting in podocin being 
accumulated in the ER had a more severe phenotype with an early-onset form of SRNS, 
than patients where podocin mutants were correctly targeted to the PM [126]. Taken 
together, these findings suggest that podocin is intracellularly trafficked to the PM via the 
classical ER/Golgi pathway. However, much of the work on podocin trafficking and binding 
partners has been done in transfected HEK293 cells rather than in the actual cells that 
express podocin physiologically, ie. the kidney podocyte. 
1.5 Hypothesis 
Proper assembly of the slit diaphragm at the plasma membrane is crucial for the 
functioning of the glomerular filtration barrier. Podocin is a scaffolding protein, essential 
for the correct trafficking and recruitment of other proteins to lipid microdomains at the 
plasma membrane. Mutations, such as R138Q, which lead to mislocalization of podocin, 




Therefore, understanding podocin trafficking and interactions could lead to new 
therapeutic targets for NS.  
1.6 Overall Aims  
The mechanism and effects of the intracellular retention of the podocin R138Q mutant 
have been previously studied in HEK293 cells, but not in its bona fide cell type, the 
podocyte. Furthermore, a key aim of glomerular research is to discover small molecules 
that correct this trafficking defect. Understanding this process, and how it is affected in 
the disease state is important to dissect. The overall aim of this work is to: 
• Create a conditional knock-in mouse model of the R140Q mutation 
• Describe the role of intracellular filaments on the ER retention of the mutant 
protein  
• Test a novel compound c407, which has shown promise in treating protein 
mistrafficking diseases, both in vitro and in vivo on podocin R138Q trafficking 
• Identify new genes mutated in NS 

















Chapter 2: Materials and Methods In Vitro 
2.1 Materials  
All the laboratory reagents were of the highest quality and purity and purchased from 
Sigma Aldrich unless otherwise specifies in the text or Appendix 1. Appendix 1 also 
contains list of solutions used, cell culture and cell extraction reagents. 
2.2 Cell lines 
The wild-type and R138Q podocin mutant conditionally immortalized human podocyte 
cell lines were developed at Bristol Renal Unit by transduction with the temperature-
sensitive SV40-T transgene as previously described [127]. These cells can proliferate at 
the permissive temperature of 33°C, and thereafter they can be transferred to the 
nonpermissive temperature of 37°C, where the cells enter growth arrest and show key 
characteristics of podocyte differentiation and function. The wild-type podocyte cell line 
is referred to as WT, while the podocin mutant podocyte cell line is called PM. The wild-
type and R138Q GFP-tagged immortalized human podocyte cell lines were created using 
PCR-based molecular cloning approach and used in experiments, where stated (These cell 
lines were established during my previous MRes project). 
All cells were grown and maintained in CO2 incubators with a temperature of 33°C/37°C, 
5% CO2 concentration and 95% relative humidity. All cell work was performed in aseptic 
conditions in a class two biological safety hood. Cell culture media was changed every 3-
4 days.  
2.2.1 Podocytes  
All human conditionally immortalised podocyte cell lines were grown in RPMI 1640 media 
with supplements as detailed in Appendix. Cells were cultured at 33°C until 70% confluent, 
and then switched to 37°C for 10-14 days differentiation. All podocyte cell lines were 
cultured under sterile conditions in tissue culture vessels including T175cm2, T75cm2 and 
T25cm2 flasks, and 6 well plates. For immunofluorescence cells were grown as described 




2.2.2 Human Embryonic Kidney (HEK) cells 
HEK 293 cells were used predominantly for virus transfection reactions. Cells were 
cultured in DMEM x1 plus Glutamax with 10% FBS (see Appendix). Cells were grown at 
37°C without thermoswitching and used for experimentation within 24-48 hours after 
seeding.  
2.2.3 Cell Passage 
Stock flasks of proliferating cells were maintained under an atmosphere of 5% (v/v) CO2 
and 95% air at the permissive temperature of 33°C for podocytes and at 37°C for HEK 293 
cells. Cells were grown to the desired confluency (70%-90%) and sub-cultured to maintain 
them at a logarithmic growth rate. For sub-culturing, growth medium was removed, and 
the adherent cells were washed with 1ml sterile trypsin. The cells were detached from 
the flask by mild tryptic digestion using 0.5 ml 0.25% Trypsin-EDTA and incubation at 37°C 
for 3-5 mins. The cells were then resuspended in the appropriate growth medium and 
aliquoted into fresh tissue culture flasks or dishes. Each time the cells were split, a 
consecutive passage number was assigned. Passages 13 to 22 were used for experiments. 
Similar growth rate and cell size were observed between WT and mutant podocytes.  
2.2.4 Cryopreservation  
To maintain stocks, cells were periodically frozen down, especially at lower passages. Cells 
were frozen down in a serum rich version of the appropriate cell media containing 
dimethyl sulphoxide (DMSO) as detailed in Appendix. Cells were stored at a high density 
in cryovials (Nalgene #5100-0001) to ensure their recovery. The cryovials were placed in 
a Mr FrostyTM Freezing Container (Thermo Scientific #5100-0001) at -80°C, which ensures 
the 1°C per minute cooling rate that is essential for successful cryopreservation of cells. 
Cells were then placed into liquid nitrogen containers for long-term storage.  
2.3 Cell Treatments 
2.3.1 NSC407882 compound treatments 
Compound 407882 was a kind gift from Prof. Aleksander Edelman (Paris, INSERM) and 
was described previously [128]. 50mM stock of 407882 was prepared in 50mM NaOH and 




and function, differentiated human podocytes were treated with 10M 407882 for 24h, 
48h and 72h. The concentration was chosen based on the work done in CF field. For 
simplicity, compound 407882 was referred to as c407 in this manuscript.  
2.4 Adhesion Assay  
Cell adhesion assays are widely used to assess the adhesion properties of many cell types, 
for example epithelial cells to the extracellular matrix, other cells, or specially coated 
surfaces. In addition, this type of assay can be used to determine the effects of various 
treatments, such as pharmacological compounds and small molecules, on the ability of 
cells to adhere. An adapted cell adhesion assay protocol is detailed here for studying the 
adhesion characteristics of human podocytes in vitro. Podocytes were grown in a T75cm2 
flask and differentiated at 37oC for 10-14 days. When fully differentiated, cells were 
trypsinised with 0.025% trypsin/EDTA for 5 min at 37oC. Podocytes were then 
resuspended in cell culture media to stop enzyme activity and collected in a 15ml falcon. 
Cells were centrifuged for 5 min at 1000 g, and then gently resuspended in 1 ml of cell 
media. 10-15μl of cells with trypan blue were pipetted onto the disposable slide and 
counted with the Luna-FL™ automated cell counter. Podocytes were again resuspended 
to a concentration of 5x105/ml in cell media. Cells were allowed to recover from 
trypsinisation in an upright falcon tube with the lid off at 37oC for 10 min. 50μl of PBS and 
50μl of cells were added to each well of a 96 well plate. Three experimental wells were 
assigned as the 100% attachment control, to which 20%, 50% and 100% of the total 
volume of cells were added. Cells were left to adhere for 45 min at 37oC. Control wells for 
100% attachment were fixed with 100 μl 4% PFA for 20 min at room temperature. 
Thereafter, the plate was tapped to remove lose and non-adherent podocytes, and 
washed twice with 100 μl PBS, and the experimental wells were then fixed with 100 μl 4% 
PFA for 20 min (note that the 100% attachment wells were not washed). The PFA was 
then washed off three times with 100μl of distilled water, and cells were stained 100μl 
0.1% crystal violet in 2% ethanol for 60 minutes at room temperature. Crystal violet was 
also added to three empty wells in order to measure binding of the dye to the plastic as a 
control. Crystal violet was removed, and wells were washed 3 times with 400μl of distilled 
water. 100μl of 10% acetic acid was added to each well to solubilise the dye. A 96 well 
plate was incubated on an orbital shaker at 150rpm for 5 minutes at room temperature. 




expressed as a percentage of 100% attachment and normalised against the adhesion of 
the human wild type podocytes cell line. 
2.5 Quantitative Polymerase Chain Reaction 
To determine gene expression levels in human podocytes, quantitative polymerase 
chain reaction (qPCR) was used, in which the quantity and quality of PCR product can be 
detected in real-time.  
2.5.1 RNA Extraction 
Podocytes were grown in 6-well plates and differentiated for 10-14 days before treatment 
and RNA isolation. Total RNA was also extracted from the untreated cells. The RNeasy 
Mini Kit (Qiagen) was used to purify high-quality RNA from cells. The manufacturer’s 
instructions were followed throughout the entire procedure. First, media was removed 
from wells, and 350μl of RLT buffer was added to each well to lyse the cells. Lysates were 
then harvested and centrifuged for 3 min at maximum speed to fully homogenize the cells. 
The supernatant was carefully removed, and 350μl of 70% ethanol was added to the 
samples and mixed well by pipetting. 700μl of each sample was then transferred to 
individual RNeasy mini columns and centrifuged for 15 s at 9000 x g. The flow-through 
was discarded, and 700μl of RW1 buffer was added to the columns. The columns were 
then centrifuged for 15 s at 9000 x g, and the flow-through was discarded again. Next, 
500μl of RPE buffer was added to the columns twice, followed by the centrifugation steps 
for 15 s or 2 min at 9000 x g. The RNeasy columns were transferred to fresh 2ml collection 
tubes and centrifuged for 1 min at full speed to dry the membrane. All buffers used were 
provided as undisclosed solutions by the manufacturer. The RNeasy spin columns were 
finally placed into new 1.5ml collection tubes, and 30μl of RNase-free water was added 
directly to the membrane of each spin column. The columns were then centrifuged for 1 
min at 8000 x g to elute the total RNA. Total RNA concentration was measured using a 
NanoDrop Spectrophotometer, and the values, as well as 280nm/260nm and 
260nm/230nm values, were noted. RNA was then stored at -80˚C until required. The same 




2.5.2 RNA to complementary DNA  
Eluted RNA was converted to single-stranded complementary DNA (cDNA) using the High 
Capacity RNA-to-cDNA™ Kit (ThermoFisher Scientific #4387406) as per manufacturer’s 
protocol. Briefly, 1μg of total RNA was used per 20μl reaction. RNA sample was diluted in 
the appropriate volume of DNase/RNase free water and made up to 9μl. 10μl of reverse 
transcription (RT) buffer mix and 1μl of RT enzyme mix was added to each sample. Tubes 
were briefly centrifuged to spin down the contents, before being placed in the Labcycler 
thermocycler (Sensoquest) to start the reverse transcription reaction. The reaction 
consisted of the following steps: incubation at 37˚C for 1h; heating to 95˚C for 5 mins; 
cooling down to 4˚C. Neat cDNA was then stored at -20˚C until required. 
2.5.3 96-well qPCR 
Human primer sequences for qPCR were obtained from a public resource for PCR primers, 
called PrimerBank (see Appendix). Primers were custom ordered from Eurofins and 
diluted to a concentration of 10μM in nuclease-free water to use in qPCR reactions. Each 
primer pair used for qPCR was initially optimised by performing serial cDNA dilutions of 
untreated cells. A 4-point standard curve with 10-fold dilutions for every new primer pair 
was then created, and R2 value was calculated (Figure 2.1). This allowed to determine the 
linear range of each reaction and the working concentration of cDNA template for 





Figure 2.1 Standard Curves. Each primer pair was first optimized by performing serial 
cDNA dilutions of untreated cells. 
 
 
QPCR was then performed using Fast SYBR® Green Real-Time PCR Master Mix as per 
manufacturer’s instructions. Each reaction consisted of the following components: 5.5μl 
of SYBR Green Fast, 0.36μl of forward (F) and reverse (R) primers, and 2μl of diluted cDNA. 
Each cDNA sample was loaded in triplicate. GAPDH and HPRT were used as housekeeping 
genes, allowing samples to be compared directly. Plates were sealed with plastic plate 
sealers and briefly centrifuged to bring down all the contents. QPCR was performed using 
protocol shown in Table 2.1 on the StepOnePlus Real-Time PCR system (Applied 
Biosystem) with the StepOne Software v2.1. The melt curves for each PCR reaction were 




Time Number of 
Cycles  




Cycling 95 15 seconds 40 
 60 60 seconds  
Melt curve 95 15 seconds 1 
 65 60 seconds  
 95 15 seconds  






Figure 2.2 Melt curves from qPCR. The single peak indicates that the cycle thresholds are 
specific to the product of interest.  
2.5.4 qPCR analysis 
The comparative delta delta Ct method was used to analyse results from QPCR.  
2.6 Protein Extraction 
2.6.1 Whole Cell lysates 
Cells cultured under sterile conditions were placed on ice and washed twice with ice cold 
phosphate buffered saline (PBS) (approximately 6 mL per T75cm2 flask). As much PBS as 
possible was removed after the second wash to prevent dilution of the sample. 500l of 
NP40 lysis buffer per T75cm2 flask was then added directly to cells. The lysis buffer 
contains a detergent to lyse the cells and a protease inhibitor cocktail. Cells were scraped 
off the flasks using a cell scraper, and the cell/lysis buffer mixtures were transferred to a 
1.5mL microfuge tubes and left on ice for 5 mins. Lysates were cleared by centrifugation 
at 13,000g (Beckman GS-15R) at 4°C for 10 mins. The supernatants containing cellular 
proteins were collected and transferred to fresh microfuge tubes. Samples were snap 
frozen in liquid nitrogen and stored at -80°C until required. 
2.6.2 GFP-Trap_A for Immunoprecipitation of GFP-Fusion Proteins  
For immunoprecipitation reactions podocytes stably expressing a GFP-tagged protein of 
interest were grown in T75 cm2 tissue culture flasks. All steps were performed on ice, and 
the centrifuge was pre-cooled to 4°C. To harvest cells, growth medium was aspirated, and 
cells were washed twice with ice-cold PBS, and then scraped off the flask with ice-cold 
NP-40 lysis buffer. Cells were transferred to a 1.5 mL microfuge tubes and placed on ice 
for 10 mins with extensive pipetting every 5 mins. Cell lysates were then centrifuged for 
10 mins at 13,000g at 4°C on a lab top centrifuge. The lysate-supernatants were 
transferred to fresh pre-cooled tubes, and pellets were discarded. Whole cell lysates were 
taken out and snap frozen at this point for long-term storage at -80°C or for use later.  
25l of GFP-Trap® _A (Chromotek) beads were added to the lysate-supernatant samples 
and incubated for an hour at 4°C under constant mixing. Samples were then spun down 
at 3,000g for 1 min at 4°C. Beads were washed three times with 500l ice-cold wash 




beads were boiled for 10 mins at 95°C to dissociate the immunocomplexes from the 
beads. The beads were then recollected by a quick centrifugation at 3,000g, and SDS-PAGE 
was performed with supernatants and whole cell lysates from the step above.  
2.6.3 Co-immunoprecipitation of Endogenous Protein  
Podocytes were grown in T175cm2 tissue culture flasks. 25l of A/G PLUS-Agarose beads 
(Santa Cruz #sc-2003) were washed twice in 200l of TNE buffer and centrifuged for 1 min 
at 3300g to equilibrate the beads. For co-immunoprecipitation, A/G PLUS-Agarose beads 
were combined with 5g of the mouse K8 monoclonal antibody or mouse IgG (Santa Cruz 
#sc2025) and mixed with 200l of TNE buffer, and left on a rotator wheel at 25rpm 
overnight at 4°C.  
The following day the conjugated beads were washed in 500l of TNE buffer and spun at 
3300g for 1 min four times to remove unbound antibody and to equilibrate the beads. 
Cells were washed twice with ice-cold PBS and then scraped into 2ml of NP-40 
immunoprecipitation buffer containing protease inhibitor cocktail. All reactions were kept 
on ice. Lysates were then centrifuged at 13,000g for 10 mins at 4°C. An aliquot of the 
whole cell lysate was taken out and kept for Western blotting. The remaining 
supernatants were transferred to fresh tubes, and the lysates were cleared with 20l of 
agarose beads and BSA to 1% for an hour with constant mixing. The beads were then 
pelleted at 2000g for 1 min, and the lysates were incubated with agarose beads coupled 
to the K8 monoclonal antibody or IgG for 4 hours on a rotating wheel at 4°C. Samples were 
then washed four times with TNE buffer and resuspended in SDS sample buffer. Proteins 
were eluted by boiling the samples for 10 mins and stored at -80°C or used immediately 
in Western Blotting to be probed with podocin antibody.  
2.7 SDS-PAGE and Western Blotting  
2.7.1 SDS-PAGE 1D gel electrophoresis 
Proteins samples were defrosted from -80˚C and separated on sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) gels. Protein extraction samples mixed with 4x SDS sample 
buffer were first denatured to unfold the protein’s tertiary structure by boiling in a hot 
block at 95°C for 10 mins. 20-30l of sample per well and 3.5 l of BLUeye prestained 




separated at a constant voltage of 150 V in 1 x running buffer for 70-90 mins using a BIO-
RAD PowerPac, or until the visible dye front had reached the bottom of the gel. The 
resolving gel was prepared using the appropriate acrylamide percentage for the molecular 
weight of the proteins being analyzed.  
2.7.2 Western Blotting 
Following SDS-PAGE, proteins were electrophoretically transferred onto gel-sized 
polyvinylidene fluoride (PVDF) membrane using a wet transfer method with Biorad Mini 
Protean II blotting apparatus. Prior to transfer, the PVDF membrane was soaked in 100% 
methanol for 5 mins in order to remove its hydrophobic coating, so that proteins can 
transfer from the gel to the membrane. Proteins were transferred at a constant current 
of 250 mA in 1 x transfer buffer for 60-90 mins depending on the size of the protein of 
interest. Higher molecular weight proteins take longer to migrate from the gel to the 
membrane. After the transfer was complete, membranes were ‘blocked’ in 5% BSA made 
up in Tris-buffered saline with 0.1% Tween-20 (TBS-T) for 1 h at room temperature with 
constant agitation. Following blocking, transfer membranes were incubated with primary 
antibodies against the protein of interest overnight at 4°C with constant agitation. Primary 
antibodies were made up in 3 % BSA at suitable dilutions. 
After overnight incubation, membranes were washed 5 times every 5 mins in 1x TBS-T to 
remove any unbound primary antibodies. Following washes, horseradish peroxidase 
(HRP)-conjugated secondary antibodies (1:5000 in 3% BSA) selected against the species 
of the primary ones were added, and membranes were incubated for 1 h at room 
temperature on a rocking platform. When specified by manufacture’s guideline, non-milk 
fat powder was used instead of BSA. 
2.7.3 Chemiluminescence and Imaging  
Membranes were washed again 5 times every 5 mins in 1x TBS-T to remove unbound 
secondary antibodies. The antibody bound to the membrane was detected using 
SuperSignal west femto maximum sensitivity substrate. Femto peroxide is the substrate 
that recognizes the peroxidase linked to the secondary antibody, while the luminol 





Western blots were analyzed using ImageJ software (imagej.nih.gov/ij) that allows the 
protein band densities to be calculated. The protein of interest was normalized to 
GAPDH/total protein, which served as a loading control. All experiments were performed 
three times to allow for the statistical analysis.  
2.8 Immunofluorescence  
2.8.1 Confocal Laser Scanning Microscopy 
To understand the trafficking of R138Q mutant podocin, and how this is affected by c407 
treatment, a detailed analysis of the localization of GFP-tagged wild-type and mutant 
podocin construct was carried out. Podocytes were cultured on glass coverslips placed 
into the six-well plates, as described above. Media was removed, and cells were washed 
twice with 2mL of PBS to remove residual paraformaldehyde and fixed with 1.5mL of 4% 
paraformaldehyde/ Ca+2/Mg+2 in PBS at room temperature (RT) for 20 mins. This step fixes 
the cells by cross-linking proteins together. The coverslips were then washed 3 times with 
2mL PBS for 5 mins, before adding 60μl of 1M glycine pH 8.5 to each well during the 
second wash to neutralize any residual crosslinking. Cells were then permeabilized with 
2mL of 0.1 % Triton X-100 in PBS for 5 mins at room temperature and washed again 3 
times with 2mL PBS for 5 mins. Next, cells were blocked in 3 % BSA in PBS for 30 mins at 
RT to inhibit non-specific binding sites, followed by incubation with primary antibody at 
the appropriate dilution in 3% BSA for an hour at RT. Cells were then washed 3 times with 
2mL PBS, removing as much liquid as possible after the third wash, prior to addition of 
secondary antibody. Species specific Alexa Fluor secondary antibody and Alexa Flour 
phalloidin have been applied for another hour of incubation at RT. Cells were then washed 
3 times in PBS followed by a final wash in MilliQ water to remove the PBS salts, and 
mounted on glass microscope slides using VECTASHIELD® HardSet Mounting Medium with 
DAPI (Vector Laboratories #H-1500). Slides were left in darkness at RT overnight to set. 
Coverslips were visualized at the Wolfson Bioimaging Facility (University of Bristol) using 
Leica SP5-AOBS confocal laser scanning microscope attached to a Leica DM I6000 inverted 




2.8.2 TIRF Microscopy 
To further understand the function of podocin at the plasma membrane, total internal 
reflection fluorescence microscopy (TIRFM) was used to investigate podocin 
trafficking/localization at or near the plasma membrane in more detail (Figure 2.3). 
Podocytes were grown in imaging dishes with glass bottom. Following washes, cells were 
fixed with 1.5mL of 4% paraformaldehyde/ Ca+2/Mg+2 in PBS at room temperature (RT) for 
20 mins, washed twice in PBS, and then permeabilized with 2mL of 0.1 % Triton X-100 in 
PBS at room temperature for 5 mins. Cells were then washed 3 times in PBS followed by 
30-minute blocking in 3% BSA in PBS. Next cells were incubated with primary antibody at 
the appropriate dilution in 3% BSA for an hour at RT. Following further washes, species 
specific Alexa Fluor secondary antibodies were applied directly to the TIRF dish for 
another hour of incubation at RT. Cells were then washed 3 times in PBS, and dishes were 
left in PBS at 4°C. Cells were imaged at the Wolfson Bioimaging Facility (University of 
Bristol) using the Leica AM TIRF MC System for total reflection fluorescence microscopy. 
The system is linked to a Leica DMI 6000 inverted epifluorescence microscope with a 
Hamamatsu C9100-13 back-thinned EM-CCD camera.  
 
 
Figure 2.3 TIRF Microscopy. Schematic illustration of TIRF microscopy, where the 
excitation (incident) beam enters the cell surface at a greater angle than the critical angle 
(θc), causing the activation of the fluorophores at the plasma membrane. This allows 
imaging of the plasma membrane in more detail, when compared to traditional 




2.9 Lipid Raft Isolation 
2.9.1 Detergent-resistant Membrane Isolation 
Cells were cultured to 80% confluency in T175cm2 flasks before being thermoswitched for 
12-day differentiation. Differentiated cells were placed on ice, washed twice with ice-cold 
PBS and scraped into 2ml of TNE (150 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, pH 7.4) 
+0.5% Triton X-100, before being homogenized through a 21-gauge needle. Cells were left 
on ice for 30 mins for the lysis reaction to occur. The lysates were then brought up to 40 
% sucrose by adding 2ml of 80 % (w/v) sucrose in TNE buffer in a 12ml ultracentrifuge 
tube and pipetting the mixture efficiently. Sucrose step gradient was then performed with 
samples as following: 5 ml of 35 % (w/v) sucrose in TNE buffer was layered on top followed 
by 1ml each of 15% sucrose, 5% sucrose and TNE. The gradients were centrifuged at 
34,000 rpm in a Sorval SW-40 swing out rotor for 18 hours at 4°C.  
2.9.2 TCA protein precipitation 
Following the centrifugal separation, 1ml fractions were taken from the top to the bottom 
of the gradient solution and allocated with fraction numbers. The lipid raft fractions 
containing the protein of interest are in Fr. No. 1 to No. 4, while non-lipid raft fractions 
are in Fr. No. 5 to No. 12 (Figure 2.4). The protein was precipitated by addition of 0.25 
volume of 100% Trichloroacetic acid (TCA). Samples were incubated for 10 mins at 4°C, 
following the centrifugation at 14,000g for 5 mins. The supernatants were removed, 
leaving protein pellets intact. Pellets were then washed 3 times with 200μl ice-cold 
acetone. Following washes pellets were dried by placing tubes in 95°C heat block for 10 
mins to drive off acetone. Fractions were resuspended in SDS-Sample buffer and boiled 





Figure 2.4 Isolation of detergent-resistant lipid rafts. 
2.10 The Proximity Ligation Assay 
To search for protein-protein interaction in vitro, the PLA was performed in podocytes 
using the Duolink™ kit (Eurogentec #DUO92191, Angers, France) according to 
manufacturer's instructions [130]. Both the number of spots and intensity were analysed. 
Chapter 3: Materials and Methods In Vivo 
3.1 Mouse model of R140Q podocin mutant 
To test whether compound 407 can rescue mutant podocin localization in vivo, a 
transgenic mouse model was developed and characterized in Chapter 4. This mouse was 
designed to carry the R140Q mutation, the mouse analogue of human R138Q, on one 
allele and floxed WT NPHS2 on the other, which can be excised upon induction with 
doxycycline.  
3.1.1 UK Animal Care Declaration 
All animals were handled in accordance with the University of Bristol and the UK Home 
Office guidelines and regulations. The following animal procedures were covered by Dr 
Becky Foster’s project license (30/3048). Animals were culled according to the Home 
Office Code of Practice-The Humane Killing of Animals under Schedule 1 to the Animals 
(Scientific Procedures) Act 1986. A personal license (PIL 30/40748) was obtained in order 





3.2 Genotyping  
Ear notches were received form Charles River Laboratories and digested in 100μl of 50mM 
NaOH at 95°C for 30-50 min to extract DNA. Prior to adding 20μl of 1M Tris-HCl (pH8) to 
neutralize each sample, samples were vortex and briefly centrifuged to spin down the 
contents. 2μl of each sample was used for the PCR reactions.  
PCR was performed using PCRBIO HS Taq DNA Polymerase (PCR Biosystems Limited, 
London, UK) according to the manufacturer’s protocol. Primers were custom ordered 
from Eurofins and diluted to a concentration of 10μM in nuclease-free water to use in 
25μl reactions (Table 3.1). To check if the reaction had worked, 20µl of each PCR reaction 




The Pod-rtTA & TetO-Cre PCR reaction was carried out at the following parameters 
Denaturation 95°C                  1 minute 
Denaturation 94°C                  45 seconds 
Annealing 51°C                          45 seconds         38 Cycles 
Extension 72°C                  1 minute                              
Final Extension 72°C                  7 minutes 
The RG reporter PCR reaction was carried out at the following parameters 
Denaturation 94°C                  3 minutes 
Denaturation 94°C                  30 seconds 
Annealing 61°C                          1 minute             35 Cycles 
Extension 72°C                  1 minute                              
Final Extension 72°C                  2 minutes 




Denaturation 94°C                  5 minutes 
Denaturation 94°C                  30 seconds 
Annealing 62°C                          45 seconds         40 Cycles 
Extension 72°C                  30 seconds  
Final Extension 72°C                  7 minutes 
The R140Q PCR reaction was carried out at the following parameters 
Denaturation 94°C                  5 minutes 
Denaturation 94°C                  45 seconds 
Annealing 52°C                          45 seconds         35 Cycles 
Extension 72°C                  45 seconds  
Final Extension 72°C                  10 minutes  
 





CCA GCA TCC CAT TAG ATA GAT GAG G NPHS2 WT allele: 236bp 
NPHS2 floxed allele: 
286bp NPHS2 flox 
R 
GCA TCC AAA TGA TCA GAG TTC CCA GG 
Pod-rtTA Pod-rtTA F CGC ACT TCA GTT ACT TCA GGT CCT C Positive band: 400bp 
Pod-rtTA R GCT TAT GCC TGA TGT TGA TGA TGC 
TetO-Cre TetO-Cre F ATG TCC AAT TTA CTG ACC G Positive band: 300bp 
TetO-Cre R CGC CGC ATA ACC AGT GAA 
R140Q R140Q F TAA TTA TAG GGC CGG TTG TC NPHS2 WT allele: 277bp 






RG WT F CTC TGC TGC CTC CTG GCT TCT Wild type allele: 330bp 
Mutant allele: 250bp RG WT R CGA GGC GGA TCA CAA GCA ATA 
RG Mut R TCA ATG GGC GGG GGT CGT T 
Table 3.1 Primers used for the genotyping. 














3.3 Drug delivery via ALZET osmotic pumps 
Pod-rtTA+/-TetO-Cre+/-NPHS2flox/R140QRG+/- or Pod-rtTA+/-TetO-Cre+/-NPHS2flox/R140QRG-/- 
transgenic mice (NPHS2flox/R140Q mice for simplicity) were used to see whether prolonged 
treatment with c407 corrected the altered podocin localization and prevented proteinuria in 
RG reporter 
Figure 3.1 Example of genotyping results. Genotyping was carried out for 10 mice 
followed by positive, negative and the no template controls for Pod-rtTA and TetO-Cre.  







these mice. ALZET Osmotic Pumps 2004 were chosen to administrate c407/0.9% NaCl at 
a continuous and controlled rate for 28 days (Figure 3.2A). Subcutaneous pump 
implantation was performed to deliver c407 dissolved in 0.9% NaCl or 0.9% NaCl for 28 
days as previously described (see Appendix 2) [131]. Mice were anaesthetized with 3% 
isoflurane (with oxygen at 1L/min), and the same level of anaesthesia was maintained 
during osmotic pump implantation. Directly after surgery, subcutaneous injection of 
rimadyl (0.1mg/kg) was administrated as analgesia. Mice were closely monitored for 24h 
and expected to make a rapid recovery from implantation of osmotic pumps. Wound clips 
were removed at day 11 post-surgery. ALZET Osmotic pumps are designed to have a fixed 
volume-delivery rate, therefore accurate calculations based on the volume of 
impermeable pump reservoir were performed to fill each pump with appropriate volume 
of c407 to achieve a dose of 22.3mg/month/mouse (based on the work done in CF field). 
It is essential to fill each ALZET pump completely with drug/saline solution under sterile 
conditions, avoiding any air bubbles being trapped within the reservoir. ALZET Osmotic 
Pumps 2004 operate based on the difference in an osmotic pressure between the osmotic 
layer of the pump and the subcutaneous tissue layer of the living animal (Figure 3.2B). The 
high osmolarity of the osmotic layer results in water being diffused into the pump through 
a semipermeable membrane creating an increase in pressure within the pump, which in 
turn displaces the contents from the pump at a controlled rate. This further results in the 
impermeable reservoir of the pump being compressed; thus, the pump is designed for a 
single use only.  
  
 
Figure 3.2 ALZET Osmotic Pump (A) in mouse (B) Alzet osmotic pump was used to deliver 




pump was taken from 
http://www.alzet.com/products/ALZET_Pumps/howdoesitwork.html 
 
3.3.1 NPHS2flox/R140Q mice 
Homozygous NPHS2 flox/flox and heterozygous NPHS2 R140Q/+ transgenic mice on a 
129Sv/PasCrl genetic background were kindly provided by Prof. Corinne Antignac 
(INSERM, Paris). These mice were transported to Charles River to be used for breeding 
with iPod mice. Pod-rtTA+/-TetO-Cre+/-NPHS2flox/R140QRG+/- mice (NPHS2flox/R140Q) on a mixed 
background were then transported from Charles River to the University of Bristol 
experimental housing facility at 4-weeks of age. Mice were allowed to settle for one week 
prior to any surgical interventions, such as implantation of the osmotic pumps. 
3.4 Urine Collection 
Urine samples were obtained from all mice prior to the start of any experimental 
procedures, such as doxycycline induction or implantation of the osmotic pumps. 
Beginning from the first week after doxycycline induction, weekly urine collections were 
performed to look for the onset and control the duration of proteinuria until the point of 
sacrificing (10-12 weeks) in NPHS2flox/R140Q mice. In the c407/saline osmotic pump model, 
urine was collected twice a week for a 28-day period. To collect samples, mice were placed 
individually in a clean plastic container and watched constantly. Once the mouse urinated, 
50-100μl of urine was pipetted off and stored at -20˚C until analysis. Siemens Multistix 
Urinalysis strips were used as a basic diagnostic tool to give an estimation of proteinuria 
as indicated by a colour change on the protein pad.  
3.4.1 Albumin Elisa 
Mouse Albumin ELISA Quantitation Set (Bethyl Laboratories #E90-134) was used to detect 
mouse albumin in urine as per manufacturer’s instructions. Frozen urine samples were 
defrosted, vortexed and diluted in Sample/Conjugate Diluent (50 mM Tris, 0.14 M NaCl, 
1% BSA, 0.05% Tween 20) based on the expected concentration of the analyte from 
Multistix Urinalysis strips analysis. All samples, as well as the standards provided by the 
manufacturer, were assayed in duplicate each time the assay was performed. 1μl of 
affinity purified antibody was diluted in 100μl of ELISA Coating buffer (0.05 M Carbonate-




to each well of the ELISA plate, which was then incubated for 1h at room temperature. 
Antibody solution was aspirated from each well, and the plate was washed five times in 
ELISA Wash solution (50 mM Tris, 0.14 M NaCl, 0.05% Tween 20, pH 8.0) before being 
blocked in ELISA Blocking solution (50 mM Tris, 0.14 M NaCl, 1% BSA, pH 8.0) for 30 min 
at room temperature. The plate was then washed again five times in Wash solution, prior 
to 100μl of standard or sample was transferred to each assigned well for 1h at room 
temperature. After incubation, the plate was washed five times in Wash solution, and 
100μl of HRP detection antibody diluted in Sample/Conjugate Diluent was transferred to 
each assigned well for 1 hour at room temperature. Another five washes were performed, 
before 100μl of TMB substrate solution was added into each well. The enzymatic colour 
reaction was allowed to develop in the dark for 15 min at room temperature. After 15 
min, the reaction was stopped by adding 100μl of ELISA Stop solution (0.18 M H2SO4). 
The plate was then gently tapped to mix the contents, and the absorbance was measured 
at 450 nm using ELISA plate reader (Opsys MR Microplate Reader, DYNEX). A standard 
curve was used to determine the amount of mouse albumin in urine.  
3.4.2 Urine Creatinine 
Urinary creatinine was measured using CREATININE (Enzymatic) kit manufactured by 
Thermo Scientific (#981845). All samples were processed as a single batch by Diagnostic 
Laboratories (Langford Veterinary Services) using a Konelab Prime 60i fully automated 
clinical chemistry analyzer (Thermo Scientific).  
3.4.3 Albumin/Creatinine Ratio (ACR) 
The mouse albumin concentration obtained from the plate reader was multiplied by the 
dilution factor to determine the amount of mouse albumin in the urine sample. Albumin 
concentrations were then converted to mg/l, while creatinine values received from 
Diagnostic Laboratories were in mmol/l. Albumin concentration (mg/l) was further 
divided by creatinine concentration (mmol/l) of the same sample to obtain 




3.5 Kidney Tissue 
The kidneys harvested from the NPHS2flox/R140Q mice were processed in several ways to 
provide a phenotypic profile for each animal after the transgene induction and to examine 
the effects of c407 on the renal function.  
3.5.1 Kidney Harvesting 
Mice were culled in accordance with Schedule 1 humane killing methods by confirmation 
of permanent cessation of the circulation. Both kidneys were collected and cut in half 
longitudinally. Half of one kidney was fixed in 10% (v/v) formalin in PBS for four days, 
before being placed in 70% ethanol. Two other halves were placed in cryovials and snap 
frozen immediately in liquid nitrogen. The cryovials were then stored at -80˚C until 
required for IF, RNA and protein extraction. The last half of the kidney was cut into 1mm 
pieces and placed in the EM buffer for fixation and storage at 4˚C. Spleen was also 
harvested and snap frozen immediately from each animal to be used as a control tissue 
for RNA and protein.  
3.5.2 Kidney Processing  
Kidney tissues were fixed in 10% (v/v) formalin, further processed and paraffin embedded 
after ethanol dehydration. Tissues were then cut by University of Bristol histopathology 
staff within the Bristol Medical School histopathology laboratory to give sections 3μm 
thick.  
3.6 Tissue Staining 
3.6.1 Periodic Acid-Schiff (PAS) staining 
PAS staining was performed on paraffin-embedded tissue sections to evaluate the degree 
of sclerosis within the glomerular tuft using PAS staining system (SIGMA-ALDRICH) as per 
manufacturer’s protocol. Slides were immersed twice in Histo-Clear II (National 
Diagnostics HS-202) for 5 min to deparaffinize sections. Sections were then rehydrated by 
passing the slides through alcohol series (100% ethanol, 90% ethanol, 70% ethanol, 50% 
ethanol) to deionized water. Slides were oxidized in periodic acid solution for 5 min at 
room temperature, before being rinsed in several changes of distilled water. Slides were 




tissue sections were counterstained in hematoxylin solution for 90 seconds and 
immediately washed again in running tap water. The sections were then dehydrated by 
being passed through alcohol series (50% ethanol, 70% ethanol, 90% ethanol, 100% 
ethanol), dried and mounted in DPX (Sigma #44581). The sections were then imaged using 
a Leica light microscope that allows to assess morphology of the kidney.  
3.6.2 Masson’s Trichrome staining 
Masson’s Trichrome staining was performed on paraffin-embedded tissue sections to 
evaluate the degree of glomerular fibrosis (collagen deposits) using Trichrome Stain 
(Masson) Kit ((SIGMA-ALDRICH) as per manufacturer’s protocol. Slides were immersed 
twice in xylene for 5 min to deparaffinize sections. Sections were then rehydrated by 
passing the slides through alcohol series (100% ethanol, 90% ethanol, 70% ethanol, 50% 
ethanol) to deionized water. Slides were stained in Weigert’s iron hematoxylin working 
solution for 5-10 mins and then rinsed in running warm tap water for another 10 mins, 
followed by the distilled water wash. The tissue sections were then stained in Biebrich 
scarlet-acid fuchsin solution for 10-15 mins, washed in distilled water and differentiated 
in phosphomolybdic-phosphotungstic acid solution for another 5-10 mins (or until 
collagen is not red). Sections were then transferred directly to aniline blue solution and 
stained for 5-10 mins, followed by a brief rinse in distilled water and differentiation in 1% 
acetic acid solution for 2-5 mins, followed by a brief wash in distilled water. The sections 
were then dehydrated by being passed through alcohol series and cleared in xylene, dried 
and mounted in DPX (Sigma #44581). The sections were then imaged using a Leica light 
microscope that allows to assess morphology of the kidney.  
3.6.3 Immunohistochemistry (IHC)  
IHC was performed with Wilm’s tumour-1 protein (WT1) antibody (Santa Cruz) to look for 
the glomerular podocyte number in mice kidney sections. Slides were immersed twice in 
histoclear for 5 min to deparaffinize sections. Sections were then rehydrated by passing 
the slides through alcohol series (100% ethanol, 90% ethanol, 70% ethanol, 50% ethanol) 
to deionized water. Slides were next boiled in the antigen retrieval buffer (10mM Sodium 
citrate tribasic, pH 6) for 10 min in microwave and allowed to cool on bench top for 30 
min. Sections were then washed in deionized water 3 times for 5 min each. PAP pen was 
used to draw around sections, which were then incubated in 3% hydrogen peroxide for 




Sections were blocked in blocking solution (5% goat serum in TBST 0.1%) for 30 min at 
room temperature. Blocking solution was then removed, and sections were incubated 
with primary antibody (20ul/sample) overnight at 4°C. Next morning, primary antibody 
was removed, and sections were washed with wash buffer (TBST 0.1%) 3 times for 5 min 
each. Sections were then covered with 1–3 drops of SignalStain® Boost Detection Reagent 
and incubated in a humidified chamber for 30 min at room temperature. Meanwhile, 1 
drop (30 µl) SignalStain® DAB Chromogen Concentrate was added to 1 ml SignalStain® 
DAB Diluent and mixed well before use (20ul/sample). Following 3 washes with wash 
buffer, SignalStain® DAB was applied to each section for 1 to 10 mins, or until the brown 
staining became apparent. Slides were then immersed in deionized water and 
counterstained with hematoxylin for 10 seconds. Next, slides were washed in tap water, 
until water became clear. The sections were then dehydrated by being passed through 
alcohol series and cleared in histoclear, dried and mounted in DPX (Sigma #44581). The 
sections were then imaged using a Leica light microscope.  
3.7 Electron Microscopy (EM) 
Kidney tissue preparation for immersion fixation involved rapid excision of animal tissues 
and immersion of small tissue pieces (1mm cubes) in fixative (2.5% glutaraldehyde in 0.1 
M cacodylate at pH 7.3) in order to get the best ultrastructure. Tissues were then washed 
in 0.1 M cacodylate buffer 3 times for 10 minutes, followed by post fixation in 1% osmium 
tetroxide in 0.1M cacodylate buffer pH 7.3 at 4 - 8°C for 1 hour. Kidney tissues were 
washed in 0.1 M cacodylate buffer for 15 minutes, followed by 3 washes in deionised 
water. Tissues were then put into 1-3% Uranyl acetate en bloc staining overnight, followed 
by 15-minute deionised water wash next morning. Kidney tissues were washed twice in 
propylene oxide for 15 minutes and infiltrated with Epon resin mix: propylene oxide (1:1) 
for 2 hours. Infiltrated tissues were then embedded in fresh Epon resin mix in a silicon 
rubber mould and left to polymerize for >24 hours at 60°C. Note, Epon resin mix consists 
of resin, hardener, accelerator and plasticiser. Finally, tissues were cut into sections 
(70nm thick) on an Ultracut S ultramicrotome, which were then stained with 3% uranyl 
acetate (5mins) and Reynolds' lead citrate (2mins) with deionised water wash in between 
and after the lead stain. Sections of glomerulus were imaged at various magnifications in 
















Chapter 4: Creation of a Conditional Knock-In Mouse Model of 
the R140Q Mutation 
4.1 Introduction  
As previously described, the podocin gene, NPHS2, encodes an integral membrane protein 
exclusively localized to the slit diaphragm of podocytes foot processes, which has been 
found to be mutated in both the familial autosomal recessive and sporadic forms of SRNS. 
Even though adult-onset cases have been identified, SRNS is most prevalent in children 
between 3 and 6 years of age [132]. Mutations in this protein comprise frameshift and 
missense changes as well as loss-of-function mutations and are spread throughout the 
entire length of the protein. Amongst more than 120 pathogenic mutations found to date, 
the most frequent variant is the p. R138Q mutation [120]. Furthermore, patients bearing 
the homozygous R138Q mutations are predicted to have a mean onset of NS before the 
first year of life, which rapidly leads to focal segmental glomerulosclerosis and 
subsequently to end-stage renal disease [124]. Effects of missense mutations of podocin 
have been studied in various cell culture models and some, along with the p. R138Q 
variant, have been shown to alter trafficking of podocin to the plasma membrane leading 
to its intracellular retention [126]. As previously established in Chapter 1, the R138Q 
podocin mutation results in the misfolded form of the protein, which is retained and 
targeted for proteasomal degradation in the ER. Several mouse models of podocin-
associated glomerulopathy have been created in the last couple of years to study the 
function of the protein during the disease course and develop new pharmacological 
strategies [133],[134]. A developmental podocin knockout mouse model (NPHS2-/-), for 
example, revealed podocin as a key player required for recruitment and assembly of 
nephrin at the slit diaphragm. Subsequently, a constitutive knock-in mouse model of the 
R140Q mutation, the mouse analogue of human R138Q mutation, was generated and 
demonstrated developmental arrest of podocytes and lethal renal failure within the first 
month of life, similar to what has been seen in the knockout model of podocin [135]. 
Recently, using Cre recombinase technology, an inducible podocin knockout model was 
created that resembled the podocin-related glomerulopathy seen in humans; however, 
this model still does not allow one to study pathogenesis of the R140Q podocin mutation 
in vivo and search for new therapeutic interventions aimed to restore the function of 




doxycycline-responsive inducible Cre recombinase knock-in mouse model of the R140Q 
mutation.  
4.1.1 Transgenic mice   
Experimental animal models have been proven to play an incredible role in biomedical 
research. Nowadays, transgenic technology is widely used in mice, which permits the 
alteration of their genetic background and therefore, the manipulation of various 
biochemical and physiological pathways and processes in the entire animal with almost 
analogous specificity observed in cell culture systems [136]. However, cell culture models 
that are currently available in the renal field do not fully recapitulate the unique three-
dimensional cytoarchitecture of podocytes or the gene expression pattern detected in 
vivo. Therefore, transgenic mouse models specifically targeting the podocyte offer new 
methods for studying the biology of this specialised glomerular epithelial cell and provide 
ways to overcome limitations seen in vitro. This cell specific expression of genes can be 
achieved using promoter elements that drive podocyte-specific expression in the kidney. 
In the case of the glomerulus, the slit diaphragm proteins, nephrin and podocin, have been 
extensively used in this way [137]. It has been previously demonstrated that nephrin is 
not a truly podocyte-specific protein and is detected in other organs, such as the pancreas 
and brain, while podocin is exclusively localized to podocytes [82]. Both NPHS1 and NPHS2 
promoter constructs have been created and linked with various transgenes to activate the 
gene expression in a podocyte-specific manner. There are circumstances, when 
researchers want to switch off gene expression in some cells. In this occasion, Cre 
recombinase will excise any piece of DNA/gene of interest flanked by loxP sites under the 
control of the cell specific promoter.  
Developmental gene knockout (KO) or knock-in (KI) systems are not always powerful 
enough to study podocyte-specific genes, such as NPHS1 and NPHS2, because up- or 
down-regulation of these genes leads to lethal renal failure at neonatal age [138]. 
Therefore, it is essential to generate mouse models that allow the inducible expression or 
knockout of genes specifically in the podocyte at any age. In glomerular research, a 
transgenic mouse model has been generated that expressed the mouse NPHS2 (podocin) 
promoter linked to a reverse tetracycline-controlled transcriptional activator (rtTA), 
which is made of a mutant tetracycline repressor protein and VP16 [134]. These mice can 
be further bred with other transgenic mice, which have genetically modified gene of 




(Tet-O) and the transcription of the target gene is activated by rtTA in the presence of 
tetracycline, so-called Tet-off system (Figure 4.1) [134]. Thus, the level of transgene 
expression can be controlled by administration of the drug, such as doxycycline, in a dose- 
and time- dependent fashion. This system can be further associated with Cre recombinase 
technology to induce the deletion of the target gene that is flanked by two loxP sites in 
the adult mouse [138]. In general, the tetracycline-controlled systems have been 
invaluable in evaluating the podocyte as a key player in glomerular function. However, 
this technology could be less than 100% effective, thus there is need to check gene 
expression in every mouse model.  
 
 
Figure 4.1 Tet-off System. A 2.5 kb fragment of the NPHS2 promoter element drives the 
expression of rtTA in podocytes. In the presence of doxycycline, rtTA binds to TetO, which 
is associated with Cre recombinase technology, and activates the deletion of the gene of 
interest, flanked by two loxP sites, in the adult mouse.  
 
4.1.2 Targeting of the murine NPHS2 allele results in expression of the 
R140Q podocin variant 
Podocin is encoded by the NPHS2 gene, which is composed of eight exons, and situated 




mRNA that encodes a 385-amino-acid protein, which shares 92% similarity with human 
podocin [111]. A mouse model carrying R140Q podocin mutation, which is analogous to 
human p.R138Q variant, was generated using a 6.6 kb targeting construct [135]. Using 
site-directed mutagenesis, the c.505G>A, c.506A>G mutations were introduced into exon 
3 of the NPHS2 gene of the targeting vector, while a phosphoglycerate kinase–
hygromycin cassette flanked by flox sites was inserted into intron 3 to select positive 
embryonic stem (ES) cell clones [135]. Following successful homologous recombination, 
two ES cell clones were selected and injected into the murine blastocyst of C57BL/6 mice 
[135]. Several rounds of breeding were undertaken to generate a mouse with germline 
incorporation of the mutant allele, which was further mated with mice constitutively 
expressing Cre recombinase that aids the removal of the floxed hygromycin insert. Using 
this model, the group of C. Antignac have demonstrated that homozygous NPHS2 
R140Q/R140Q mice die within the first week of life with some mice dying during 
embryogenesis, while heterozygous NPHS2 R140Q/+ mice did not develop albuminuria or any 
renal anomalies [135]. The above models are characterized either by severe renal 
phenotype resulting in early death or by insufficient expression of the mutated protein. 
Therefore, the conditional inactivation of wild-type protein is essential to elucidate the 












4.2 Methods  
4.2.1 Breeding of a conditional knock-in mouse model of R140Q mutation  
Homozygous NPHS2 flox/flox and heterozygous NPHS2 R140Q/+ transgenic mice on a 
129Sv/PasCrl genetic background were a kind gift from Prof. Corinne Antignac (INSERM, 
Paris). Homozygous NPHS2 flox/flox mice were generated to carry a floxed NPHS2 exon 2 
alleles, which can be excised, when Cre recombinase is expressed leading to a conditional 
podocin inactivation in mature kidneys (Figure 4.2) [139]. 
 
Figure 4.2 NPHS2 floxed allele. Mice were created to carry a floxed NPHS2 exon 2 alleles, 
which can be excised using Cre recombinase.  
 
Initially, two lines NPHS2 flox/flox and NPHS2 R140Q/+ were crossed to generate heterozygous 
NPHS2 flox/R140Q offspring mice, which were used for further breeding (Figure 4.3). 
Subsequently, the NPHS2 flox/R140Q mice were crossed with a transgenic iPod male mouse 
model of a mixed genetic background (a kind gift from Prof. Richard Coward) for 
generation of the inducible mice line. The iPod male mouse model is composed of three 
genes: 1) rtTA that is under the control of a 2.5 kb NPHS2 promoter driving podocyte-
specific expression of rtTA  [134]; 2) TetO-Cre that is under the control of a tetO, to which 
the rtTA protein binds in the presence of tetracycline or analog, such as doxycycline, thus 
allowing Cre recombinase expression; 3) RG reporter, also known as mT/mG, that is a red 
green fluorescent reporter under the control of a CMV enhancer/chicken beta actin core 
promoter that regulates the expression of a loxP-flanked tdTomato reporter element 
followed by a polyadenylation signal and EGFP reporter element. Mouse podocyte cells 
initially express red fluorescence, and then green fluorescence in the presence of Cre 
recombinase, which can excise floxed tdTomato reporter, suggesting that the R140Q 




transgenic mice had the specified cassette of genes (Pod-rtTA+/-TetO-Cre+/-
NPHS2flox/R140QRG+/- or Pod-rtTA+/-TetO-Cre+/-NPHS2flox/R140QRG-/-) and were used for the 
final experiments. For simplicity, the mice were called NPHS2flox/R140Q in this document.  
 
 
Figure 4.3 An example of breeding strategy used to generate a Conditional Knock-In 
Mouse Model of the R140Q Mutation. Only male mice had TetO-Cre and were used for 
further breeding, as TetO-Cre was shown to be leaky in females.  
 
4.2.2 Experimental design for phenotypic characterization  
Postnatal induction of R140Q hemizygosity in NPHS2flox/R140Q mice was achieved by 
administration of doxycycline at 2 mg/ml in 5% sucrose dissolved in drinking water for 
three weeks. Doxycycline, a tetracycline derivative, binds with high affinity to rtTA, thus 
inducing a Tet-off system in transgenic mice. Doxycycline was shown to have an excellent 
medical safety record and deep tissue penetration with relatively low toxicity in 
eukaryotic cells [140]. Doxycycline was made fresh every 4 days and administered in black 




given the same volume of drinking water without doxycycline. Other control groups of 
mice, which lacked either Pod-rtTA or TetO-Cre or both, received the equivalent volume 
of drinking water with doxycycline at the same concentration as used for the experimental 
mice. The rationale for having mice without the Pod-rtTA gene, for example, is that the 
induction efficiency of the floxed wild-type podocin can be monitored. Mice were 
maintained and managed by skilled animal technicians in the pathogen-free conditions of 
ASU unit, University of Bristol. 
Beginning from the first week after doxycycline induction, weekly urine collections were 
performed to look for the onset and control the duration of proteinuria until the point of 
sacrificing. Animals were sacrificed at weeks 10-12 after doxycycline administration. In 
case of weight loss (over 10%), the affected animal was culled immediately. At designated 
experimental time points mice were maintained under general anaesthesia with 
isoflurane, and 1 ml of blood was withdrawn by cardiac puncture. Animals were 
subsequently sacrificed by Schedule 1, and both kidneys were removed (flash frozen, put 
in PFA or EM buffer). Samples were collected and used for RNA and protein extraction, 
immunofluorescence studies, immunohistochemistry and electron microscopy. Urine 
albumin concentration was analysed using human albumin ELISA kit (Bethyl Laboratories). 
Whole blood samples were sent to Diagnostic Laboratories (Langford Vets, University of 
Bristol) to measure serum creatinine, albumin and urea. Urine samples were also sent to 













4.3.1 NPHS2flox/R140Q mice develop NS and end-stage kidney disease 
Doxycycline induction of a hemizygous state in the NPHS2flox/R140Q mice led to severe 
proteinuria detectable within few days, which peaked to a maximum at 2-4 weeks after 
induction of NPHS2null/R140Q and was maintained at week 12 (Figure 4.4a). Consequently, 
there was a continuous decrease in proteinuria observed from week 6 in experimental 
animals, but it still stayed elevated compared to controls until the point of sacrificing at 
12 weeks. This is due to the deformation of the kidney structure. Furthermore, proteinuric 
animals had a significantly reduced weight gain from week 8 onward, when compared to 
healthy controls (Figure 4.4c). The NPHS2null/R140Q animals presented with 
hypoalbuminemia (g/L), hypercholesterolemia (mmol/L), uremia (mmol/L) and 



















Figure 4.4 NPHS2flox/R140Q mice develop NS. (a) Doxycycline induced mice develop massive 
proteinuria from week 2 onward. One-way ANOVA (p≤0.05). (b) NPHS2null/R140Q mice 
demonstrate significantly diminished creatinine clearance, uremia, hypoalbuminemia and 
hypercholesterolemia at 12 weeks (One-way ANOVA (p≤0.05) vs. controls at the same 
time point). (c) Weight loss is observed in experimental animals from week 8 onward. (d) 
SDS-PAGE urine protein analysis. Coomassie staining displays albuminuria in doxycycline-





4.3.2 Loss of podocin mRNA expression by 12 weeks  
QPCR analysis was performed to look for total, floxed WT and R140Q NPHS2 expressions 
at 4 and 12 weeks, in order to check the doxycycline efficiency. Interestingly, R140Q 
podocin mRNA expression was similar to healthy controls at 4 weeks, but then dropped 
significantly at 12 weeks after induction (Figure 4.5a, b). The expression of WT podocin 
mRNA decreased at 4 weeks after doxycycline induction of the heterozygous state, as 
anticipated (Figure 4.5a). Furthermore, total loss of podocin mRNA expression was 




Figure 4.5 mRNA expression analysis. (a) Diseased mice displayed a loss of total, floxed 
WT and R140Q podocin mRNA expressions at week 4. One-way ANOVA (p≤0.05) (b) Total 
loss of total, floxed WT and R140Q podocin mRNA expressions was observed at week 12 







4.3.3 Total podocin loss associated with the loss of podocytes in 
NPHS2flox/R140Q mice 
Immunofluorescence studies were performed to detect the level of total podocin protein 
in glomeruli of healthy and NPHS2null/R140Q animals at the point of sacrificing. The loss of 
podocin expression in NPHS2null/R140Q mice was observed at 12 weeks after doxycycline 
induction compared to healthy controls (Figure 4.6). The loss of podocin was associated 
with the reduction in number of podocytes in the induced animals during the course of 
the disease. Furthermore, the nephrin expression was also reduced in proteinuric animals.  
 
Figure 4.6 Loss of podocin is observed in NPHS2flox/R140Q mice. Podocin (green), nephrin 
(red) and nucleus (blue) staining of glomeruli of healthy and NPHS2null/R140Q animals at the 
point of sacrificing (12 weeks). Water and doxycycline control groups show normal 
expression of podocin and nephrin in glomerulus. Doxycycline induced animals 
demonstrate podocin and nephrin loss at the point of end stage renal disease. 





4.3.4 Proteinuric animals develop global glomerulosclerosis 
Control healthy animals had normal glomeruli on PAS stain without GBM thickening and 
mesangial cell deposits. Bowman’s space and proximal tubules were well-defined (Figure 
4.7). The NPHS2flox/R140Q mice displayed 100% of globally sclerosed glomeruli with 
collapsed Bowman’s capsules space at 12 weeks after induction. In addition, the 
proteinuric mice demonstrated podocyte loss and developed tubulointerstitial 
fibrosis with prominent proteinaceous casts. Electron microscopy further revealed 
podocyte foot process effacement and global fusion with GBM thickening in induced 
animals relative to two control groups (Figure 4.7).  
 
Figure 4.7 NPHS2flox/R140Q mice present with global glomerulosclerosis at 12 weeks. 
PAS staining was performed to look for glomerular lesions in induced animals. 
Magnification, x40. Scale bar, 25 µm. Ultrastructural studies demonstrated podocyte foot 
processes effacement in NPHS2null/R140Q mice compared to regular foot processes seen in 
healthy control animals on the opposite side of endothelial cells (indicated by arrows). 





Previous hereditary podocytopathy mouse models, such as NPHS2 KO mice, 
Nphs2R140Q/R140Q KI mice and laminin beta2 mutant mice, develop severe renal phenotype 
and have an average survival time of 4-23 days depending on the genetic background 
[141]. This results in insufficient characterization of the disease course because of the 
incomplete nephrogenesis with the mouse models not being suitable for preclinical 
testing of novel pharmacological strategies, such as antiproteinuric therapies, due to early 
demise. To investigate the pathogenesis of podocin mutation related to NS at postnatal 
life, a transgenic mouse line was generated using a doxycycline-inducible Cre recombinase 
technology that results in conditional inactivation of wild-type protein expression [138]. 
Postnatal induction of R140Q hemizygosity in the NPHS2flox/R140Q mice results in massive 
proteinuria within the first few days, which is maximal at 3-4 weeks. Moreover, other 
biochemical aspects of NS, such as hypoalbuminemia (low albumin level in the blood), 
uremia and insufficient creatinine clearance, were observed in proteinuric animals, 
suggesting that the animals progressed to end-stage renal disease (ESRD). The 
progression to ESRD is closely correlated with the development of focal segmental 
glomerulosclerosis (FSGS), which is largely detected in renal biopsies of patients bearing 
NPHS2 mutations, such as R138Q [132]. Based on the work done by the group of C. 
Antignac, it was concluded that the NPHS2flox/R140Q mice initially developed FSGS, where 
only some of the glomeruli were affected, that quickly progressed to almost all glomeruli 
being scarred and sclerosed at 12 weeks. At the point of sacrificing, kidneys of the 
NPHS2flox/R140Q mice showed global glomerulosclerosis and severe interstitial fibrosis, as 
indicated by significant PAS staining (Figure 4.7). Furthermore, capsular adhesion and 
collapse of the glomerular tip was observed in some variants along with podocyte loss. In 
support of this notion, the link between podocyte depletion and glomerulosclerosis has 
been previously described in a transgenic rat stain expressing human diphtheria toxin (DT) 
receptor transgene [142]. Wharram et al. have identified three stages of podocyte 
depletion from glomeruli, when DT was injected into transgenic but not wild-type rats in 
a dose-dependent manner, supporting the theory that podocyte depletion may be a 
major driver for glomerulosclerosis in humans [142]. In addition, tubulointerstitial fibrosis 
was observed in induced animals at the end stage of the disease. The degree of 
tubulointerstitial damage is in parallel with the severity of proteinuria, as it has been 
previously shown that nephrotic range albuminuria is toxic to tubular and interstitial 




inducible R140Q-podocin mouse model recently generated by the group of C. Antignac, 
with almost same time course of proteinuria and uremia [133].  
It still remains unclear what mechanisms cause podocytes to detach and, specifically, 
whether this loss is prompted by podocyte cell death, such as apoptosis, or due to the loss 
of adhesive characteristics of the cells [144]. Further ultrastructural assessment using 
electron microscopy was performed to evaluate for probable foot process fusion and 
effacement as a result of disease. Electron microscopy findings demonstrated that the 
development of high-grade proteinuria is closely associated with widespread podocyte 
foot process effacement and global fusion (Figure 4.7). These findings are in agreement 
with previously published mouse models of hereditary podocytopathies, such as the 
inducible podocin knockout model, where foot process effacement evolved with the 
inactivation of podocin in the mature kidneys [139]. Podocyte loss in the mouse model 
described is most likely caused by podocin being misfolded and retained in the ER, 
therefore it cannot maintain podocyte foot processes structure and function. 
Finally, immunofluorescence staining, and qPCR analysis were undertaken to establish the 
degree of podocin loss on the molecular level following postnatal induction of R140Q 
hemizygosity in NPHS2flox/R140Q mice. When global glomerulosclerosis was fully established 
at 12 weeks, a loss of podocin protein was observed compared to control animals. Due to 
the excision of the floxed wild-type allele in NPHS2null/R140Q mice, the expression of wild-
type podocin mRNA was reduced, resulting in the diminished expression of podocin 
protein. Interestingly, R140Q mRNA expression remained elevated at this stage of the 
disease, suggesting the decreased podocin protein is a definite consequence of the 
mutant protein intracellular retention and proteasomal degradation as previously 
observed in vitro for the R138Q podocin mutation [145]. 
In conclusion, the inducible NPHS2flox/R140Q mouse model described here closely 
recapitulates the commonest human mutation. Furthermore, this novel model of 
nephrotic syndrome highlights some significant phenotypic differences observed in 
previous inducible knockout mouse models of podocin, such as the inducible podocin 
knockout model. Therefore, the ability to produce a mutant podocin protein with 
defective folding and subsequent retention in the ER provides the model ideal for 
pharmacological screening of chaperone compounds in vivo that could correct trafficking 




Chapter 5: Disruption of cytokeratin-8 interaction with R138Q 
podocin corrects its functional defect both in vitro and in 
vivo 
5.1 Introduction  
5.1.1 Keratin 8 (K8) – a novel candidate for targeting and degradation of 
misfolded proteins 
As highlighted in Chapter 1, NS is the most prevalent kidney disease in children, which is 
caused by altered function of the GFB resulting in proteinuria, edema and 
hypoalbuminemia. Even though primary causes of NS vary, steroid therapy is used 
clinically to descriptively classify NS as SSNS and SRNS. Amongst SRNS genes discovered 
to date, mutations in the NPHS2 gene encoding podocin represent the major and the most 
frequent cause of the disease. This integral protein with a membrane domain forms a 
hairpin like structure with both the C- and N-terminal tails facing the cytoplasm. The 
R138Q podocin mutation in exon 3 was found to be present in 57.5% of families carrying 
two disease-causing mutations, confirming the role of R138Q as a founder mutation [125]. 
The R138Q mutation produces a folded form of the protein that is retained in the 
endoplasmic reticulum (ER). Consequently, this has prompted an intensive search for a 
possible strategy that might recover defects in cell sorting of podocin mutant.  
Studies performed by Colas et al. identified an interaction between the major disease 
causing mutant of the cystic fibrosis transmembrane conductance regulator (CFTR) with 
the cytokeratin network [130]. This 1480-amino acid protein is a PKA-activated chloride 
channel, which shares structural similarities with members of the ATP-binding cassette 
transporters family and is made of two transmembrane domains (MSDs), two nucleotide-
binding domains (NBDs) and one regulatory domain (R-domain) (Figure 5.1) [146]. Gating 
function of the channel is highly dependent on the phosphorylation of the R-domain by 
PKA and is further controlled by the binding and hydrolysis of the ATP molecules to the 
NBDs [147]. Cystic fibrosis (CF) is a fatal autosomal recessive genetic disorder affecting 
mostly the lungs, caused by mutations in the gene encoding the chloride channel CFTR 
[148]. In particular, the F508del mutation of CFTR was found to be present in more than 




of phenylalanine 508 in NBD1 domain of CFTR results in a more severe form of CF [148]. 
Similar to the R138Q mutation, F508del mutation generates an improperly folded form of 
the CFTR, which is mostly retained and targeted for proteasomal degradation in the ER, 
however, when it reaches the plasma membrane, the function is moderately restored 
[149]. Therefore, due to the defective trafficking or folding, there is a significant reduction 
of functional CFTR at the apical plasma membrane, moreover, the amount of F508del-
CFTR that in some cases is targeted to its destination displays a dysfunction, known as a 
gating defect [150],[151]. Apart from having effects on epithelial cell function, CFTR 
mutations can have an impact on bone homeostasis, as CF patients in some cases present 
with low bone mineral density [152]. The study by Colas et al. provided a new insight into 
a previously unknown mechanism that plays a role in the retention of F508del-CFTR. Using 
an immunoprecipitation approach, a physical interaction between K8 and F508del-
CFTR has been demonstrated in cultured cells, suggesting a critical role of K8 in the 
mutant CFTR retention [130]. Furthermore, inhibition of this interaction is able to recover 
the function of the mutant at the cell surface [130].  
 
Figure 5.1 Schematic representation of CFTR. CFTR is made up of two transmembrane 
domains (MSDs), two nucleotide binding domains (NBDs) and a regulatory domain (R-
domain). Adapted from Kalid et al [153]. 
 
Since the discovery of mutations in podocin as the cause of NS, further studies are 
required to elucidate potential pharmacological advancements to rectify the dysfunction 
of the mutated proteins. For missense mutations, such as F508del-CFTR and R138Q 
podocin, small correctors (molecules) have to be discovered/created to target the mutant 
proteins back to the plasma membrane and to improve their function, also known as 
potentiators [154]. One of the successful potentiators developed for CF patients bearing 
the G551D mutation is a VX-770/Ivacaftor, which demonstrates a clinical benefit with no 
major side effects [155]. Nevertheless, protein folding and targeting are complex 
intracellular processes, which makes it difficult to develop correctors. Indeed, such 




for podocytopathies. Recently, using virtual screening approach together with molecular 
dynamic simulation methods Wieczorek and Zielenkiewicz discovered four novel effective 
molecules, which are able to rescue trafficking defect of F508del-CFTR, resulting in 
correction of CFTR function both in CF human cells and mice [156], [157]. One of the most 
promising chemical molecules identified is 407882 (c407 in this document) that has two 
phenylphosphinic acid moieties and is able to inhibit K8-F508del-CFTR interaction [157]. 
Furthermore, 407882 is a water-soluble molecule, which makes it beneficial for drug 
administration, and was shown to target mutant CFTR back to the plasma membrane 
[157]. 
Based on the work done by Colas et al. that proposed a potential dominant role for 
cytokeratin network in mutant CFTR misprocessing, it was suggested that K8 and/or K18 
might also interact with the R138Q podocin mutant. Therefore, the aim of the present 
work was to confirm and study the molecular basis of this interaction on R138Q podocin 
localization and function, and to examine whether the disruption of this interaction with 
K8 silencing or compound c407 rescues R138Q podocin localization back to the plasma 
membrane and corrects its functional defect both in vitro and in vivo. 
5.1.2 Cytoplasmic intermediate filaments  
The major structural feature of all eukaryotic cells is their well-developed cytoskeletal 
systems, which predict cell shape and perform a variety of cellular roles. As previously 
underlined in Chapter 1, two major ubiquitously expressed cytoskeletal polymers (F-actin 
and microtubules) are present in the cytoplasm of eukaryotic cells, however a third 
fibrous polymer of the cell, called intermediate filaments (IFs), was more recently 
discovered [158]. A minimum of 67 genes have been revealed to date through molecular 
cloning to encode various IF proteins, which are able to self-assemble into the distinctive 
10-12-nm-wide cytoskeletal filaments as seen by electron microscopy [159]. Analogously 
to microtubules and microfilaments, IFs are dynamically regulated in cells, where they 
participate in the cytoskeletal network assembly of the cytoplasm and interact with a 
variety of cellular proteins [160]. These flexible fibrous polymers can also be found in the 
nuclear lamina meshwork, where they are recognized as nuclear lamins [160]. 
Nonetheless, there are a number of characteristics that are unique to intermediate 
filaments and apart from their shared conserved substructure and sequence, these 
features include: a lack of the intrinsic polarity that is fundamental for actin filaments and 




filament dynamics is independent of ATP binding and hydrolysis [161],[162],[163]. 
Therefore, IFs are predicted to carry out functions that are distinct from those of other 
cytoskeletal polymers. At the protein level, IFs can be classified into five groups according 
to polymerization properties. Type I and Type II groups consist of proteins that correspond 
to cytokeratins (CKs), while Type III group includes proteins, such as vimentins and 
desmin, which are produced by mesenchyme derived cells [160]. Type IV group includes 
proteins, such as internexin, which are mainly found in neuronal cells, while Type V is 
defined by proteins located in the nuclear envelope [160].  
All IF proteins show a characteristic ternary domain architecture with a centrally located 
domain being of a fixed length, either 310 or 352 amino acid residues [158]. However, the 
main universal feature of these proteins is the presence of a common motif composed of 
four alpha-helical segments found in the central domain, which is flanked by nonhelical 
linker parts, head and tail (Figure 5.2) [160]. Both head and tail domains can vary in length 
and primary structure adding to the heterogeneity found within the family of IFs [158]. 
The alpha helix displays a specific distribution of hydrophobic/apolar amino acid residues, 
thus allowing helices to connect in a coiled coil rod, the foundation block of the IF proteins 
[164]. This rod domain further contains highly conserved signature motifs located at the 
N- and C-termini. Moreover, IF proteins can associate with other IF-associated proteins to 
form macrofibrils in secondary structure, which are connected by disulfide bonds in the 
case of hair for example [160]. These proteins are also known to undergo several post-
translational modifications (PTMs), such as phosphorylation and glycosylation [160]. The 
interactions with other proteins and these PTMs together are essential in establishing the 
function and dynamics of IFs in various cell types, some of which will be outlined in the 
next section.  
 
Figure 5.2 Secondary structure of IF proteins. A centrally located domain is composed of 
4 alpha-helical segments (subdomains 1A, 1B, 2A and 2B) forming a rod in secondary 
structure, which features highly conserved signature motifs at its N- and C-termini 
(magenta coloured boxes). This rod domain is further flanked by non-helical head and tail 





5.1.3 Keratins - versatile structures    
Keratins (Ks), the distinctive IF proteins produced by epithelial cells, represent the largest 
class of cytoskeletal proteins, which are subdivided into Type I ‘acidic’ (K9–K28) and Type 
II ‘ neutral-basic’ (K1–K8 and K71–K80) subgroups [165]. Keratin IFs are typically arranged 
into bundles, called tonofibrils, which are able to form cage-like structures surrounding 
the nucleus and expanding from the perinuclear space towards the cell periphery, where 
they make contacts with adhesive structures [160]. Keratin IFs form non-covalent 
heteropolymers of members of Type I and Type II subgroups by antiparallel binding, which 
are expressed as pairs in a highly differentiation-specific way, suggesting functional 
diversity [163]. The pairs formed can be further classified into two or three expression 
subgroups: simple keratins, keratinocytes and structural keratins [160]. The keratin 
K8/K18 pair represents the first IFs expressed during embryogenesis, and is present in all 
simple epithelial linings, such as kidney and liver, in the adult [163]. When an impaired 
pairing of individual keratins occurs, the mispaired keratin either enters a degradation 
pathway or associates with proteins involved in apoptosis and signalling events, thus 
opening a window into a new field of CKs functions [160].  
Considering their mechanical roles, keratin IFs have been recognized as stable cytoskeletal 
elements, however, it is now well known that they are highly dynamic scaffolds in vivo 
[160]. These proteins participate in the variety of cellular events, including migration and 
proliferation, and particularly, IFs aid the positioning of intracellular organelles [160]. 
Nevertheless, the discovery of cytokeratin mutations and their study in mice allowed to 
determine some non-structural functions of these proteins, some of which are highlighted 
below [166]. These proteins show selective localization in epithelial cells, where they 
protect epithelia against multiple kinds of stresses and perform a number of additional 
roles [165]. Other additional functions include their involvement in cell signalling and 
apoptosis, along with unique properties emerging, which are keratin specific and tissue 
specific (Figure 5.3). The keratin IFs are able to protect cells against mechanical stress by 
forming a 3-D complex that interacts with desmosomes and hemidesmosomes [160]. The 
work done on hepatocytes isolated from mice synthesizing keratins that have mutated 
phosphorylation sites has revealed that these cells were able to cope with mechanical 
stress subsequent to liver perfusion [167]. Therefore it has been suggested that, during 
stress, K8 and possibly other keratins might act as a ‘sponge’ for stress-activated 




keratins in cell cycle regulation has been recently acknowledged from the work on 
hepatocytes of K8- and K18-deficient mice, where an elevated accumulation of the 
signalling 14-3-3σ protein was observed [168]. Enlarged nuclei with a doubled DNA 
content have been found in these cells, suggesting that absence of keratin filaments 
results in cells entering the S-G2 cell cycle phase, which further causes abnormal 
cytokinesis [168]. Keratins have been also seen to play a role in the attenuation of 
apoptosis both at the death receptor and cellular levels [160]. The evidence comes from 
the work done on the keratin 8-deprived hepatocytes isolated from K8-null mice, which 
are more resistant to Fas (tumour necrosis factor alpha receptor)-mediated apoptosis in 
comparison to wild-type cells [169]. IFs are implicated in the trafficking of proteins to their 
intracellular compartments in polarized epithelia, while they also participate in the 
regulation of ion transporters, such as CFTR (cystic fibrosis transmembrane conductance 
regulator) [160]. The latter is based on the evidence that CFTR is mistargeted in K8-null 
small intestine villi [170]. Here, most of the work will be focused on the IF-related protein-




















5.2.1 Intracellular localization of R138Q podocin  
In this work, the consequence of the R138Q mutation of podocin was studied by 
expressing the GFP-tagged wild-type and R138Q mutant podocins in human podocytes. 
As shown in Figure 5.4a, wild-type podocin displayed a localization consisting of a plasma 
membrane staining and an intracellular vesicular labelling. On the other hand, the R138Q 
podocin mutant was strongly retained in the ER as seen by complete colocalization with 
calnexin, an ER marker. Furthermore, TIRF microscopy was used to access podocin’s 
localization at or near the plasma membrane in human podocytes. The fluorescence signal 
obtained by TIRF imaging represents podocin within 100 nm of the coverslip, i.e., in or in 
close proximity to the plasma membrane. As anticipated, the mutant podocin displayed 
no plasma membrane labelling, while wild-type podocin localized with F-Actin at the 
plasma membrane (Figure 5.4b). Next, flotation gradient centrifugation was used to 
determine whether the disease-causing mutation of podocin interfered with its ability to 
associate with lipid rafts. In flotation gradients of Triton X-100 extracts, detergent-
insoluble raft-associated proteins represent the first 4 fractions, while detergent-soluble 
protein/protein complexes are identified as fractions 5-8, 9-12. The quality and purity of 
the fractions were examined using Flotillin-1, as a lipid raft marker. As expected, the 
R138Q podocin was not able to associate with lipid rafts due to its ER retention, causing 
lipid raft composition to be altered, while wild-type podocin reached the plasma 





Figure 5.3 A schematic diagram demonstrating the main functions of keratins. Four 
main roles, namely structural, differentiation, protein targeting and synthesis, are in 
agreement with the rest of functional aspects. The role of keratins as disease 
biomarkers is connected to the main functions by grey lines. Modified from Brouillard 





Figure 5.4 Effect of disease-causing podocin mutation. (a) Confocal images showing 
immunofluorescence staining of GFP-tagged podocin constructs and the ER protein 
calnexin in conditionally immortalized human podocytes. Scale bar=1 µm. (b) TIRF images 
of GFP-tagged podocin constructs and an early endosomal marker-1 (EEA1) with F-actin. 
Scale bar=0.75 µm. (c) Lipid raft isolation experiment of either the endogenous wild-type 
or mutant podocins. The quality and purity of the fractions were examined using Flotillin-




5.2.2 Keratin 8/18 and podocin  
In the next set of experiments, the intracellular distribution of keratin 8/18 was analysed 
in human podocytes expressing either the GFP-tagged wild-type or R138Q mutant 
podocins using confocal microscopy. Localization of keratin 8 and WT podocin was shown 
by immunofluorescence at the cytosol level, while localization of keratin 8 was seen in the 
perinuclear area in close vicinity of R138Q podocin (Figure 5.5a). Here, the keratin 8 
expression was elevated, and the keratin 8 network reorganized itself to form the 
meshwork like structure, further trapping the mutant protein in the ER. The same was 
observed for Keratin 18 (Figure 5.5b). Next, an immunoblot and qPCR analyses were 
performed to verify the expression of K8 and K18 on both the protein and RNA levels in 
human podocytes. The results confirmed the observation of the immunofluorescence 
analysis, both K8/K18 protein and RNA expression levels were significantly higher in 



















Figure 5.5 Analysis of Keratin 8/18 expression levels using Immunofluorescence, 




human podocytes. Scale bar=1 µm. (c, c’) Immunoblot analysis showing that K8 and K18 
protein expression levels are significantly increased in mutant podocytes compared to 
wild-type cells. The expression profiles were normalized to the total protein. 
Differentiated ciPod n=3, two-tailed T-test *≤0.05. (d, d’) RNA expression profiles of 
keratin 8 and keratin 18, two-tailed T-test *≤0.05 
 
5.2.3 Keratin 8-R138Q podocin interaction 
Co-immunoprecipitation (Co-IP) assay of endogenous proteins was then conducted to see 
whether keratin 8 and podocin interact directly in human podocytes. Co-
immunoprecipitation experiments demonstrated that endogenous keratin 8 preferably 
interacts with R138Q podocin over its wild-type counterpart (Figure 5.6a). To further 
search for K8-Podocin interaction in vitro, the Proximity Ligation Assay (PLA) was 
performed using the Duolink™ kit (Eurogentec, Angers, France) according to 
manufacturer's instructions in human podocytes derived from either a healthy patient or 
a patient with R138Q mutation [130]. The PLA is a highly sensitive and specific approach 
that can directly detect proteins and protein interactions within 40 nm proximity in 
unmodified cells. A <40 nm proximity between K8 and R138Q podocin was identified in 
human podocytes (Figure 5.6b). This strongly suggests that detectable physical interaction 














Figure 5.6 Keratin 8-R138Q podocin interaction. (a) Anti-keratin 8 antibody precipitated 
keratin 8 and co-precipitated podocin in human podocytes derived from the patient with 
R138Q mutation. Mouse-IgG was used as a control. (b) Molecular proximity of K8 and wild-
type/R138Q podocin in human podocytes. No primary antibody was used as a negative 
control. Scale bar=20 µm. (b’) Results are representative of 3 independent experiments, 
two-tailed T-test *≤0.05.  
 
5.2.4 Silencing of keratin 8 restores R138Q podocin’s localization and 
function in patient’s cells  
In this study, we hypothesized that inhibiting the keratin 8-R138Q podocin interaction by 
keratin 8 silencing might rescue the lipid raft association of the mutant protein and restore 
its functional defect. All K8-shRNA sequences considerably decreased K8 expression in 
both human podocyte cell lines (Figure 5.7a). The effect of keratin 8-shRNA on lipid raft 




mutant podocytes restored the association of the R138Q podocin with lipid rafts, while 
non-coding shRNA had no effect (Figure 5.7b). Finally, to evaluate the functional impact 
of keratin 8 silencing, human K8 shRNA podocyte cells were further analysed for their 
adhesive capacity in an in vitro adhesive assay. There was a significant decrease in 
adhesion observed in GAPDH shRNA mutant podocyte cell line, when compared to the 
wild-type control. This adhesive defect of the mutant podocyte cell line was rescued by 
knock-out of K8 (Figure 5.7c).  
 
Figure 5.7 Effects of Keratin 8 silencing. (a) Western blots of protein lysates showing the 
effect of shRNA treatment on keratin 8 expression in human podocytes derived either from 
a healthy patient or a patient with the R138Q mutation. Cells were treated either with 
non-coding shRNA, GAPDH shRNA or with Seq. 1/2/3 of K8 KO shRNA. (b, b’) Seq.1 of K8 
KO shRNA restored the association of R138Q podocin with lipid rats. The quality and purity 
of the fractions were examined using Flotillin-1 as lipid raft marker and the exclusion of 
CD99 as a marker for non-raft associated proteins. Two-tailed T-test *≤0.05. (c) The 
adhesive defect of the cells was rescued using K8 shRNA sequence, while GAPDH shRNA 




5.2.5 Molecular modelling  
To create the computer model of podocin and to study the effect of R138Q mutation on 
podocin structure, the podocin amino acid sequence was submitted to the HHPred server 
(Protein homology detection and structure prediction server). The best matching 
structure found was the stomatin core domain from Pyrococcus horikoshii (PDB 3BK6) 
providing a gapless alignment between residues 158-316 with a 37% sequence identity in 
this region. The model shows that R138 is in a sequence of hydrophobic amino acids (IFRL; 
136-139) located on the tip of a reverse turn in the middle of a -sheet, flanked on either 
side by loops bearing mostly hydrophobic residues (Figure 5.8a). Consequently, the 
R138Q mutation, replacing the positively charged arginine with the neutral residue 
glutamine, will essentially merge these regions into a larger hydrophobic patch. This is 
illustrated in Figure 5.8b, where the protein surface is coloured by amino acid 
hydrophobicity. Computer modelling was used to see if the c407 ligand could bind 
adjacent to the hydrophobic patch on the R138Q surface. Some molecular dynamic 
simulations were further performed to see if the c407 remains bound under more realistic 
conditions. It was predicted that c407 fits into the hydrophobic pocket of R138Q podocin 






Figure 5.8 Molecular modelling. (a) A ribbon diagram of the podocin model (residues 95-
314) showing the amino acid side chains as sticks and coloured by atom type. Arginine 138 
is labelled. (b) Surface representations of the wild type podocin model (upper) and the 
R138Q mutant (lower) coloured by hydrophobicity. The scale on the left is the 
experimental free energy of transfer from water to octanol in kcal/mol. (c) The c407 ligand 
is able to fit into the hydrophobic pocket created by the replacement of arginine residue 
at position 138. 
 
5.2.6 Novel compound c407 disrupts Keratin 8-R138Q podocin interaction 
Since c407 disrupts the F508del-CFTR interaction, immunofluorescence studies were 
performed to see whether treatment with c407 for 24 hours rescued mutant podocin 
localization back to the plasma membrane. Figure 5.9a shows immunofluorescence 
images of Podocin (green) and Keratin 8 (red) in human podocytes stably expressing either 
GFP-tagged WT podocin or R138Q podocin mutant in control conditions and after 
treatment with c407. Treatment with c407 rescued the localization of mutant podocin 
back to the plasma membrane by decreasing the keratin 8 expression, as anticipated. 
Furthermore, c407 treatment decreased both keratin 8 and 18 protein expression levels 




derived from the patient with the R138Q mutation were treated with c407 to see whether 
it caused the targeted disruption of the protein-protein interaction in vitro. As expected, 
c407 interrupted the K8-R138Q podocin interaction, while treatment with NaOH had no 
effect, where the K8-R138Q podocin interaction was observed using Co-IP (Figure 5.9c). 
 
Figure 5.9 Treatment with c407 rescues R138Q podocin localization. (a) Podocytes stably expressing either 
WT podocin or R138Q podocin mutant were subjected to GFP and K8 immunodetection and analysed by 
confocal microscopy. (b) Effect of c407 treatment on the K8/18 protein expression levels in human podocytes 
derived from either a healthy patient or a patient with R138Q mutation. Results are representative of 3 
independent experiments, two-tailed T-test *≤0.05. (c) Co-IP was performed to see whether treatment with 




5.2.7 Inhibition of K8-R138Q podocin interaction by c407 restores function 
of the mutant protein  
To test whether compound c407 interrupts the direct protein-protein interaction, a series 
of proximity ligation experiments were performed on human podocytes derived either 
from a healthy patient or patient with the R138Q mutation. Figure 5.10a demonstrates 
that there is a significant decrease in K8-R138Q podocin interaction, indicated by green 
fluorescent spots, after treating cells with c407. Furthermore, that disruption of 
interaction results in functional correction of the mutant protein as seen by two sets of 
experiments: (a) lipid raft isolation in human mutant podocytes and (b) an adhesion assay. 
Subsequent treatment with c407 allowed the association of mutant podocin with 
specialized lipid raft microdomains of the plasma membrane, while also restored the lipid 
raft composition (Figure 5.10b). Finally, the adhesive defect of the mutant cells was 





Figure 5.10 Effect of c407 on the R138Q podocin's function and interaction. (a) Proximity 
ligation assay of K8 and WT/R138Q podocin in human podocytes derived either from a 
healthy patient or a patient with the R138Q mutation. Green spots correspond to 
K8/Podocin interaction (proximity of less than 40nm). Nuclei (DAPI) is stained blue. 
Results are representative of at least three independent experiments; one-way ANOVA 
p≤0.05. (b) R138Q podocin is found in the DRM fraction (fraction 1-4) after c407 
treatment. Flotillin-1, raft marker, was used to confirm the purity of the fractions. Two-
tailed T-test *≤0.05. (c) Cell adhesion assay to see the effect of c407 on the adhesion of 






5.2.8 C407 treatment prevents the development of NS in the transgenic 
mouse model of the R140Q mutation 
To understand whether c407 could prevent the development of NS in NPHS2flox/R140Q mice, 
doxycycline was administrated for 3 weeks, at the same time as one group was treated 
with c407 and another group was treated with vehicle (0.9% NaCl) for 4 weeks via osmotic 
mini pumps. A third group with vehicle pumps served as no disease controls and was 
administrated drinking water for the duration of the study. Doxycycline animals treated 
with vehicle, developed proteinuria within the first two weeks of R140Q hemizygosity 
induction, which peaked at Week 4 as anticipated (Figure 5.11a). On the other hand, c407 
treatment significantly prevented the development of proteinuria in R140Q mice starting 
from Week 2, and also reversed podocytes loss associated with NS induced by doxycycline 
(Figure 5.11 a, c). Furthermore, experimental mice displayed hypercholesterolemia, 
hypoalbuminemia and high blood urea levels, all of which were prevented upon 
administration of c407 (Figure 5.11b). Finally, the Cre/LoxP system was used to excise 
podocin on both alleles in NPHS2 flox/flox mice leading to total podocin knockout in these 
animals. These mice were used as controls to prove the theory that c407 only targets 
misfolded proteins. These mice displayed no change in proteinuria levels upon 






Figure 5.11 In vivo treatment with c407. (a) Induced control mice developed severe 
proteinuria at 4 weeks after doxycycline induction, which was prevented in c407 mice. 
One-way ANOVA p≤0.05. (b) Control mice display hypercholesterolemia, 
hypoalbuminemia and high blood urea levels, all of which is prevented upon 
administration of c407. One-way ANOVA p≤0.05. (c) Treatment with c407 prevented 
podocyte loss in R140Q mice. One-way ANOVA p≤0.05. (d) c407 treatment had no effect 






5.2.9 Immunofluorescence and histological analysis 
Decreased podocin protein expression was observed at week 4 in in NPHS2flox/R140Q mice, 
which were given doxycycline for 3 weeks compared to that of healthy controls. In vivo 
c407 treatment restored mutant podocin localization back to the plasma membrane as 
seen by immunofluorescence on mice kidney sections (Figure 5.12a). By contrast, Keratin 
8 was seen to be upregulated in glomeruli of mutant mice, and treatment with c407 
resulted in restoration of minimal keratin 8 expression in glomeruli (Figure 5.12b). 
Furthermore, foot process effacement, FSGS and glomerulosclerosis with protein casts 
were observed in those animals, as seen on kidney histology and EM, which were 



























Figure 5.12 Immunofluorescence and histological analysis. (a) Confocal images of 
podocin and nephrin performed on the NPHS2flox/R140Q mice kidney sections. Treatment 
with c407 rescued the mutant podocin localization in mice. Magnification, X63; zoom, 
x8. (b) Keratin 8 expression was elevated in glomeruli of diseased animals, which was 
brought back to normal upon treatment with c407, as seen by immunofluorescence. 
Magnification, X63; zoom, x8. (c) These mice developed FSGS with the large percentage 
of glomeruli affected by sclerosis. Mice that were given the c407 compound 
demonstrated normal histology. Magnification, x40. Podocytes loss and effacement was 















As mentioned in Chapter 1, NS is a common renal disease identified in children of a wide 
range of ages and characterized as a triad of proteinuria, hypoalbuminemia and edema. 
Although a lot of work has been previously done to identify molecular mechanisms 
underlying the nature of the disease, NS is still categorised as steroid-sensitive NS (SSNS) 
and steroid-resistant NS  (SRNS) based on the patient’s response to steroid therapy [125]. 
Using a positional cloning approach, a number of genes mutated in SRNS patients have 
been revealed, amongst which mutations in NPHS2 gene represented the most common 
cause [171]. Histologically, patients bearing NPHS2 mutations initially present with 
minimal glomerular changes observed on renal biopsies, which at later stages develop 
into FSGS and in the majority of clinical cases rapidly progress to ESRD [69].  
The majority of the functional studies addressing the link between cytoskeleton and 
proteins, such as podocin, have been mainly focused so far on proteins that are involved 
in the actin network assembly. The mode of action of both microtubules and actin 
filaments in protein sorting and trafficking is well described; while no significant 
information is present that reveals the role of IFs in this process. However, a number of 
recent studies have identified new functions of IFs, specifically of keratins, filament-
forming proteins of epithelial cells. Indeed, a novel function of IFs in vesicular trafficking 
and protein sorting was first reported in the studies showing altered trafficking of 
membrane proteins, such as CFTR [130].  
The present work describes previously unknown machinery that plays role in the R138Q 
podocin intracellular retention and firmly suggests that keratin 8-R138Q podocin 
association facilitates the ER retention of the mutant protein. Keratins have been 
previously reported to be up-regulated in different disease models, such as animal models 
of pancreas and liver injury [172], while keratin 8 and 18 have been recently described to 
be novel markers of renal epithelial cell injury [173]. The current study reports an 
increased expression of keratin 8 in R138Q mutant human podocytes for the first time. 
There is also an increased interaction of keratin 8 and podocin in close vicinity of the ER 
in R138Q mutant cells, which is reversed by treating cells with c407, resulting in the rescue 
of the mutant protein localization. When addressing the localization of R138Q podocin at 
the plasma membrane, the crucial question to ask is whether the mutant protein is 
functioning correctly. Nephrotic Syndrome podocytes are known to display changes in 




Excitingly, a full rescue of adhesion function of mutant cells was achieved upon treatment 
with c407. Furthermore, computer modelling of protein folding revealed that R138Q 
mutation creates a large hydrophobic region, which becomes exposed for interaction with 
other proteins or small molecules, such as c407. Therefore, it is tempting to hypothesize 
that K8-R138Q interaction occurs as a result of the appearance of this hydrophobic 
pocket, and that c407 is able to bind to this pocket blocking the interaction with K8 and 
thus allowing for the correction of the R138Q podocin processing defect.  
The importance of the keratin 8 network in the mutant protein misprocessing is supported 
in the context of the cell response to keratin 8 silencing. Various gene-ablation techniques 
have been widely used therapeutically to target lipopolysaccharide-induced proteinuria 
[175] or renal fibrosis [176] for example. Furthermore, keratin 8 mRNA silencing has been 
studied experimentally; K8 knockdown in the cancer cell line MCF-7 resulted in loss of cell 
adhesion and collective migration, and an abolition of multidrug-resistant phenotype of 
these cells [177],[178]. To date, to our knowledge, keratin 8 expression was modified for 
the first time in the kidney field in the current study. Here, we demonstrate that keratin 
8 shRNA results in the correct localization of the R138Q mutant protein and the recovery 
of its function. The fact that silencing of keratin 8 recovers the function of the mutant 
protein further suggests that keratin 8 network can act as a potential therapeutic target. 
This agrees with the study showing that the specific modification of the K18 expression 
by RNA silencing led to the regulated transport of F508del-CFTR to the plasma membrane 
in transfected HeLa cells [179].  
Finally, we demonstrate the cellular effects of the small molecule c407 in vitro translated 
into a therapeutic benefit in vivo. Indeed, 28-day treatment with c407 in NPHS2flox/R140Q 
mice resulted in the prevention and treatment of proteinuria with normal kidney 
histology observed. Control mice were treated with saline for the same period of time; 
these mice underwent a gradual increase in proteinuria, which was associated with high 
plasma urea level and hypoalbuminemia. Furthermore, histological analysis revealed that 
c407 prohibited the development of glomerulosclerosis, which was observed in control 
mice at the point of sacrificing. Next, electron microscopy was employed to visualize 
podocyte foot processes and to see whether c407 can prevented podocyte foot process 
effacement, as this biological process is characteristic of many renal diseases. Similar 
therapeutic effect was seen in F508del-Cftr mice, where short-term administration of 




This work suggests that keratin 8, and potentially keratin 18, inhibit the transport of the 
mutant protein to the plasma membrane. Although there are yet questions that remain 
unanswered regarding the precise mechanism of this interaction, this work demonstrated 
physical interaction between K8 and R138Q mutant, suggesting that keratin 8 forms a 
complex with the R138Q-podocin. Furthermore, the disruption of this interaction with 
c407 lead to the localization of the functional protein back to the plasma membrane, and 
that R138Q podocin delocalization was associated with the keratin 8 network 
reconstitution. However, both the wild-type and mutant proteins must be purified to 
identify the direct site of the interaction with keratin 8 using Biocore or an equivalent 
chemical assay. Moreover, it has previously been shown that interaction of the mutant 
protein with the keratin network leads to it being degraded via the ubiquitin-mediated 
degradation pathway. Therefore, it would be interesting to determine whether the K8-
R138Q podocin interaction targets mutant protein towards the proteasomal machinery 
[181]. Another important aspect that must be addressed in the future is to study the 
expression of K8 in kidney biopsies of patients with the R138Q mutation. Finally, the 
eventual aim for this project is to further develop the c407 compound within an industry 
partnership leading to clinical trial in patients with R138Q mutation.  
In summary, our study provides direct evidence that keratin 8 is involved in the podocyte 
dysfunction associated with the most common R138Q podocin mutation in NS. This work 
further demonstrates that pharmacological targeting of keratin 8 with c407 in vivo leads 
to prevention and correction of proteinuria in NPHS2flox/R140Q mice. Moreover, this study 
provides a solid foundation for developing other pharmacological compounds targeting 
















Chapter 6: TBC1D8B Loss-of-Function Mutations Lead to X-
Linked Nephrotic Syndrome via Defective Trafficking 
Pathways 
6.1 Introduction  
In the past 20 years, advances in genetic testing and techniques have increased our 
understanding of the pathogenesis of genetic SRNS. To date, various genetic mutations of 
structural and functional molecules of podocytes are known to result in serious 
abnormalities of the podocytes themselves, but also of neighbouring structures, leading 
to, for example, sclerotic lesions, such as FSGS, and, importantly, more remain to be 
identified [70]. These mutations have been found in a number of intracellular 
compartments of the podocyte, and play an important role in actin cytoskeleton 
dynamics, podocyte integrity and Golgi/mitochondrial function [182]. Furthermore, more 
details continue to emerge on the defects in intracellular protein trafficking, that result in 
the accumulation and aggregation of proteins in various subcellular compartments, and 
appear to be a prevalent causative factor in the development of numerous human 
diseases, such as NS [183]. In most cases, this disruption in protein trafficking occurs due 
to mutations, which give rise to abnormal protein structures as a result of protein 
malfunction [184]. Therefore, this study was undertaken in collaboration with Dr. 
Guillaume Dorval (Laboratory of Hereditary Kidney Diseases, Imagine Institute, INSERM 
U1163, Paris Descartes University, 75015 Paris, France) to identify a novel gene mutated 
in X-linked NS and study the effects of the mutation on the podocyte structure and 
function both in vitro and in vivo.  
6.1.1 New gene mutated in SRNS identified by exome sequencing 
Through studies aiming at identifying new genes mutated in SRNS in two families, we 
identified a potential actor of endosomal trafficking. The first family (family A) was from 
Ecuador and presented with isolated congenital SRNS consistent with an X-linked 
inheritance. Pedigree and clinical features are described in Figure 6.1A. Briefly, affected 
females (I-2 and II-2) exhibited non-nephrotic proteinuria, while affected boys (II-1, II-3, 
and II-4) developed congenital or early-onset NS. All pregnancies were marked by pre-




biopsy revealed FSGS lesions and electron microscopy (EM) showed FP effacement, a 
hallmark of NS [185]. The pro-band (II-4) reached ESKD by the age of 2.8 years and did not 
exhibit recurrence after kidney transplantation. By exome sequencing (ES), we identified 
a c.738G>C variant in TBC1D8B (GenBank: NM_198881.1; HGNC:24715) localized on 
chromosome X (Figure 6.1B). This missense variant (p.Gln246His) was defined as probably 
damaging by pathogenicity prediction software. Through a European collaborative 
network (Eurenomics), we identified another sporadic SRNS-affected individual (II-2) in a 
family (family B) originated from the UK Renal Rare Disease Registry  (RaDaR  #425), with 
a missense c.872T>C (p.Phe291Ser) variant in the same gene (Figures 6.1C and 6.1D). This 
variant also displayed highly pathogenic scores. The affected individual (II-2), a male from 
European ancestry presenting with early-onset SRNS at the age of 2 years, had no other 
systemic features. Kidney biopsy revealed global sclerosis on light microscopy and FP 
effacement on EM (Figure 6.1E). He reached ESKD by the age of 9 years and underwent 
kidney transplantation a year later. Both mutations segregated with the affected status in 
the respective families and were, respectively, present in 1/27, 314 (with no hemizygous) 
and absent from gnomAD database in the population-matched control subjects. Both 
mutations involved residues conserved from C. elegans to H. sapiens. Based on the 
information above, it was concluded that the TBC1D8B is novel gene associated with X-
Linked NS. TBC1D8B, encoded by the TBC1D8B gene, is an uncharacterized Rab-GTPase-














Figure 6.1 Clinical and genetic information for Families A and B. (A and C) Family 
pedigrees for families A (A) and B (C). In family A, the proband (II-4) and his brothers (II-1 
and II-3) developed congenital nephrotic syndrome, while the individual from family B (II-
2) developed an early-onset nephrotic syndrome. Arrows indicate probands. TBC1D8B 
mutations c.738G>C and c.872T>C were detected in affected subjects and carriers of 
families A and B, respectively. (B and D) Exome sequencing revealed two distinct missense 
variants in TBC1D8B (c.738G>C and c.872T>C). Segregation of variants was confirmed by 
Sanger sequencing in both families. (E) Electron microscopy image from affected 
individual from family B (II-2) harbouring the p.Phe291Ser mutation revealed foot 
processes effacement (white arrowheads) (scale bar, 2μm). 
 
6.1.2 Link between Rab and TBC (Tre-2/Bub2/Cdc16) 
Rab proteins are small GTPases that represent evolutionarily conserved family of 
membrane proteins, which regulate and participate in a variety of membrane trafficking 
pathways, such as formation, transport, tethering and fusion of vesicles with the target 
plasma membrane, thus acting as molecular switches [186], [187]. Principally, Rabs switch 




an inactive GDP (guanosine diphosphate) state, where the active form is the one that 
allows vesicles/organelles trafficking through interaction with a Rab partner, also known 
as Rab effector [188]. Furthermore, that Rab cycle is controlled by two activating enzymes, 
GEF (guanine-nucleotide-exchange factor) and GAP (GTPase-activating protein) (Figure 
6.2) [188]. Accordingly, recognition and characterization of these GEFs and GAPs at the 
molecular level are essential in order to understand Rab-mediated trafficking events at 
the plasma membrane of eukaryotic cells.  
 
 
Figure 6.2 Cartoon illustration of a Rab cycle. The active GTP form of Rab is targeted to a 
designated vesicle/organelle and facilitates its transport through interaction with Rab 
effector molecule. Adapted from Fukuda [188]. 
Recently developed tools, such as Rab panels, allowed for the systemic identification of the 
mammalian Rab proteins and their isoforms [189], while also made it possible to 
comprehensively validate a variety of Rab effector molecules [190]. Apart from Rab3-GAP and 
Rab3-GEF, majority of the mammalian GEFs and GAPs have been so far identified based 
on the sequence homology to budding yeast GEFs and GAPs [191]. Furthermore, there is 
only a small number of mammal-specific GEFs verified on the basis of the sequence 
homology to yeast GEFs [188]. Contrarily, Rab-GAPs identified so far in mammals, 
excluding Rab3-GAP, have a TBC domain, which is made of approximately 200 amino acids 
[188]. Interestingly, there are more than 40 different TBC proteins described in humans 
and mice, which runs in parallel with the number of proteins in Rab superfamily, for 
example Rab1-43 in humans [188]. Recent studies have demonstrated that some TBC 
proteins have the Rab-GTPase (Rab-GAP) activity, thus believed to be involved in 




One such protein is TBC1D8B, a member of the TBC domain protein family (Tre-
2/Bub2/CDC16). Like other TBC proteins, TBC1D8B may function as a Rab-Gap by binding 
to specific Rab proteins and stimulating their GTPase activity [188]. Interestingly, in 
addition to its Rab-GAP (TBC) domain, TBC1D8B contains one GRAM domain repeated two 
times, which allows binding to lipid rafts, critical elements of SD signalling in podocytes 
[105],[192]. The two mutations described above are localized within each GRAM domain 
(Figure 6.3). TBC1D8B also possesses an EF-Hand domain localized at the C-terminal 
extremity. EF-hand domain has been previously described in other proteins as a calcium-
binding regulation site, which may downregulate the protein activity, when bound to Ca2+ 
[192]. A second isoform of TBC1D8B results from alternative splicing events in intron 11 
and leads to a shorter 632-amino acid protein, lacking the C-terminal extremity of the 
Rab-GAP domain and the entire EF-like domain. However, the catalytic residues (Arg534 
and Glu574) are present in both protein isoforms. Interestingly, the role of TBC1D8B has 
never been explored either in cell lines or animal models. To our knowledge, results 
obtained in the current work reveal the role of TBC1D8B in the kidney or more precisely, 
the podocyte, for the first time. 
 
 
Figure 6.3 Cartoon illustrating the structure of the TBC1D8B protein. Mutations are 
localized in GRAM domains at the N-terminus. Catalytic residues on the Rab-GAP domain 
are maintained. C-terminal EF-hand domain is not conserved in isoform 2. 
6.2 Materials and Methods 
6.2.1 Cell culture 
Conditionally immortalized human podocytes [127] were routinely cultured at 33°C in 
RPMI‐1640 (Gibco® , Life Technologies), supplemented with 10% FBS, 1% 




Technologies), and then, for experiments, cells were thermoswitched to 37°C for 10‐14 
days differentiation. Cells used in this study were tested mycoplasma‐free.   
6.2.2 Antibodies, reagents and chemical compounds 
The following antibodies were used in this study: mouse monoclonal antibodies (mAb) 
against GFP (Roche, Cat. No. 118144600001), c‐myc epitope (Thermo Fisher, MS‐139‐P), 
synaptopodin (Progen, Cat. No. 65194), and rabbit polyclonal antibodies against TBC1D8B 
(Abcam, ab121780) and Rab11b (Atlas Antibodies HPA054396). Alexa‐fluor 647 Phalloidin 
from ThermoFischer was used for IF (catA22287). For IF, Alexa Fluor‐conjugated 
secondary antibodies (donkey anti‐rabbit Alexa Fluor 488 and anti‐mouse Alexa Fluor 546) 
were obtained from Life Technologies (ThermoFischer). Alexa‐Fluor 555‐ or 546‐ 
conjugated transferrin (Life Technologies, Cat.No T35352 and T23364, respectively, used 
at 25µg/mL) was used for trafficking experiments. 
6.2.3 Immunofluorescence and vesicular trafficking studies 
Podocytes were grown on type I collagen‐coated coverslips and either used to study the 
subcellular localization of endogenous TBC1D8B, or transiently transfected the next day 
using FuGENE® HD Transfection Reagent (Promega) or used for endocytosis and recycling 
experiments. Cells were fixed in 4% paraformaldehyde (PFA) for 20 min at room 
temperature and alternatively permeabilized with 0.3% Triton TX‐100 (Sigma) in 1X PBS 
for 4 min (for endogenous TBC1D8B) or directly incubated in blocking buffer containing 
5% bovine serum albumin (BSA, Sigma) for 1h at room temperature. Cells were then 
incubated in the appropriate primary and secondary antibodies for 1h each at room 
temperature. Nuclei were stained with Hoechst (#33342, Sigma) at room temperature for 
8 min.    
For transferrin endocytosis (uptake) / recycling (chase), we performed two different 
analyses:  
For endocytosis study (transferrin uptake), fibroblasts were starved at 37°C for 60 min in 
transferrin‐ free OptiMEM medium supplemented with 1% Bovine Serum Albumin (BSA) 
and podocytes were starved in Serum‐Free‐Medium devoid of transferrin (SFM, Gibco® , 
Life Technologies) with 1% Bovine Serum Albumin (BSA) for 60 min. Cells were then 
incubated on ice at 4°C in the same ice‐cold medium enriched with Alexa‐Fluor (AF‐555)‐




bind its receptor but inhibit internalization. After 30 min incubation, cells were washed in 
cold 1X PBS. Cells were then incubated at 37°C in their respective medium (with 
transferrin) to allow transferrin internalization and blocked in 4% PFA at different time 
points. Mutated cells were compared to control cells for each time point.  
For recycling study (chase study), cells were incubated in Alexa‐conjugated transferring‐
enriched appropriate medium (25µg/mL) supplemented with 1% BSA for 60min at room 
temperature for fibroblasts and 120 min for podocytes. Cells were then washed with 1X 
PBS, incubated in transferrin‐free medium and then fixed in 4% PFA at different time 
points. For endocytosis and recycling, all time points’ results were normalized to T0.    
As transferrin endocytosis/recycling kinetics are dependent on cell types, the use of 
different time points for transferrin endocytosis and chase in podocytes vs fibroblasts 
were based on the manufacturer instructions (30 to 60 min for endocytosis) and literature 
when available [127],[193][194], and empirically on our personal lab experience. 
Experiments were repeated 3 times and at least 20 cells were analysed in each time point 
experiment. Microscope settings were the same within each independent experiment. 
The integrated fluorescence intensity in each independent cell was measured and the 
background fluorescence intensity was subtracted to calculate corrected total cell 
fluorescence (CTCF) using the following equation CTCF=integrated density − (area of 
selected cell × mean background fluorescence per unit area). All time point values were 
normalized to T0 (maximum intensity). Whereas microscope settings allow to easily 
detect a 50% decrease of fluorescence in cells, they were imprecise for lower values. Thus, 
recycling assay was stopped, when the fluorescence intensity in WT cells reached 50% of 
the intensity measured at T0. 
Immunofluorescence studies of endogenous TBC1D8B were performed as described 
above on 10 µm‐frozen sections of human embryonic kidney biopsies obtained from The 
Department of Pathology of Necker‐Enfants Malades Hospital (Paris, France). 
6.2.4 Scratch assay and adhesion assay 
This was performed as previously described by Vollenbroker et al. [193]. In brief, 
confluent differentiated human podocytes were cultured in six‐well plates and scratched 
with two lines at 90° angle with a sterile 0.4‐mm 200‐μl Gilson style extension length tip. 




Medium was removed, and cells were trypsinised until all cells were suspended, which 
was optically controlled. Cells were plated into 96‐well plates and three experimental 
wells were assigned as the 100% attachment control, to which 20%, 50% and 100% of the 
total volume of cells were added. Cells were left to adhere for 45 min at 37 oC. Control 
wells for 100% attachment were fixed with 100 μl 4% PFA for 20 min at room 
temperature. Thereafter, the plate was tapped to remove lose and non‐adherent 
podocytes, and washed twice with 100 μl PBS, and the experimental wells were then fixed 
with 100 μl 4% PFA for 20 min. Cells were stained with 100μl of 0.1% crystal violet in 2% 
ethanol for 60 minutes at room temperature. Absorbance on the plate was measured at 
570nM in a plate reader. Results were depicted as a percentage of 100% adherent cells 
and normalized against the adhesion of the human wild type podocytes. 
6.2.5 Zebrafish experiments  
All results obtained from Zebrafish were performed by Dr. Guillaume Dorval (Laboratory 
of Hereditary Kidney Diseases, Imagine Institute, INSERM U1163, Paris Descartes 
University, 75015 Paris, France) 
 
6.3 Results  
6.3.1 Localization and phenotype studies of TBC1D8B in human kidney 
and podocytes 
Immunofluorescence studies in human kidneys revealed the presence of TBC1D8B both 
in glomerular podocytes and tubules at early stages (25 weeks) and in mature kidney. In 
glomeruli, TBC1D8B colocalized with synaptopodin a specific cytosolic protein (Figure 
6.4A). To further comprehend the role of TBC1D8B, we undertook functional studies in 
human podocytes. Podocytes from individual B (harbouring the p. Phe291Ser variant) 
were conditionally immortalized from the affected individual’s nephrectomy specimen 
using the published methodology [127]. Podocytes from affected individual B exhibited 
alterations in actin cytoskeleton organization, and TBC1D8B displayed an intracellular 
vesicular localization as shown in Figure 6.4B. Furthermore, mutated podocytes 




Podocytes from individual A were not available, since he underwent bilateral 
nephrectomy several years before. 
 
 
Figure 6.4 TBC1D8B localization and phenotype observed in mutated podocytes. (A) 
Immunofluorescence studies were performed on human fetal kidney at 25 gestational 
weeks (top) and in mature kidney in a healthy 7-year-old male (bottom). TBC1D8B 
displayed a glomerular localization with partial colocalization with synaptopodin, a 
cytosolic podocyte protein (scale bar, 20 μm). (B) In immunofluorescence experiments 
in immortalized podocytes, TBC1D8B displayed an intracellular vesicular expression. F-
actin cytoskeleton was detected by immunofluorescence with phalloidin staining. p. 




cytoskeleton. Original magnification ×63. (C) Cell adhesion was measured with a 
spectrophotometer at 570 nm optical density (n = 3, ∗∗p < 0.01, mean ± SEM). (D) Human 
podocyte cell motility and migration were measured by scratch assays. Number of cells 
per unit was significantly higher in the WT group 12 hr after the scratch, as shown on the 
graph on right (n = 3, ∗∗∗p < 0.0001, mean ± SEM). 
 
6.3.2 Zebrafish studies 
In zebrafish, pericardial oedema was observed in >95% of both MOSPLICE and 
MOATG morphants at 96 hpf, whereas it was found in fewer than 2% of control MO fish at 
96 hpf (Figure 6.5A and B). Furthermore, an identical phenotype was obtained in 
the tbc1d8b−/− fish with the expected Mendelian ratio (n = 261; 22.9% phenotype 
in tbcd8b+/−offspring; Figure 6.5C). histological analysis showed a retracted glomerulus in 
an enlarged Bowman’s capsule in tbc1d8b−/− fish compared to controls (Figure 6.5D). EM 
revealed significant FP effacement and disappearance of SD in tbc1d8b−/− KO fish 
compared to controls (Figure 6.5E). The following results were obtained by Dr. Guillaume 
Dorval (Paris, France).  
 
Figure 6.5 Phenotype observed in TBC1D8B KO and KD Zebrafish. (A) KO fish displayed 




MOATG and MOSPLICE also exhibited pericardial edema in more than 95% fish whereas 
MOCONTROL did not (n > 200, ∗∗∗p < 0.0001, mean ± SEM). (C) tbc1d8b+/− offspring displayed 
pericardial edema with a Mendelian ratio. (D) Regular optical microscopy revealed a 
retracted glomerulus (∗) in an enlarged Bowman’s capsule (white circle) in 
mutated tbc1d8b−/− fish compared to control (scale bar, 15 μm). (D) Electron Microscopy 
findings showed a mixture of foot processes (FP) effacement (∗) with regular FP (black 
arrowheads). Graph on the right shows a significantly lower rate of FP per uM 
in tbc1d8b−/− fish compared to control (n = 3 fish per condition, ∗∗∗p < 0.001, mean ± SEM). 
6.3.3 TBC1D8B interaction and trafficking 
Transferrin endocytosis and recycling assays were performed in wild type and affected 
individuals’ podocytes. Fluorescence intensity progressively increased in 
control podocytes, whereas it increased much more slowly in mutated podocytes 
harbouring the p.Phe291Ser mutation, suggesting an endocytosis defect (Figure 6.6A,B). 
Measuring recycling of fluorescently labelled transferrin in WT and mutant podocytes 
revealed persistence of fluorescence 45 min after internalization in mutant cells, while it 
reached 50% of T0 intensity in control podocytes, indicating a delay in recycling processes 
in mutant cells (Figure 6.6C,D). Next, co-IP studies were done in HEK293T cells, where the 
Rab-binding domain (RBD) of TBC1D8B was seen to interact with a dominant active, GTP-
bound, mutant of Rab11b (DA-Rab11b), but not with DA-Rab11a (Figure 6.6F). Moreover, 
endogenous IP was performed to look for the interaction between TBC1D8B and DA-






Figure 6.6 TBC1D8B interaction and effect of mutations of vesicular trafficking. (A and 
B) Transferrin uptake is evaluated by incubation with fluorescently labelled transferrin. 
Graph B represents the quantification of normalized fluorescence in both mutated and 
control cells (∗∗∗p < 0.001, mean ± SEM; scale bar, 25 μm). (C and D) Transferrin chase 
evaluates the recycling process in podocytes. Graph D represents the quantification of 
normalized fluorescence in both mutated and control cells (∗∗∗p < 0.001 at 45 min, mean 
± SEM; scale bar, 25 μm). (E) Construct used for to perform co-immunoprecipitation with 
a specific plasmid harbouring only the TBC1D8B Rab-binding domain (RBD) tagged with 
the myc epitope, and under the CMV promoter. (F) In co-transfected HEK293T, the (myc-
)RBD of TBC1D8B is able to interact with Dominant Active (DA)-Rab11b but not DA-
Rab11A nor DA-Rab5. (G) The endogenous TBC1D8B protein interacts with transfected 






As described in Chapter 1, SRNS is a glomerular disease characterized by massive 
proteinuria, most often associated with FSGS [185]. SRNS is responsible for chronic kidney 
disease and accounts for 15% of ESKD cases in individuals under 25 years of age [195]. 
Identification of monogenic causes of SRNS involving more than 40 genes has helped 
decipher podocyte physiology [196], [197]. By exome sequencing, we identified missense 
mutations in TBC1D8B in two families with an X-linked early-onset SRNS with FSGS. Many 
studies have reported a strong relationship between the SD and the actin cytoskeleton 
[197], and the role of vesicular trafficking has been well established in the maintenance 
of SD complexes [198],[199]. Nevertheless, intracellular transport defects have rarely 
been related to monogenic SRNS [200].  
As mentioned above, TBC1D8B may act as Rab-GAP, promoting GTP hydrolysis in specific 
Rab proteins [201]. In mammalian cells including podocytes, Rab-GTPases are mostly 
involved in vesicular trafficking [202],[203]. To further analyse the role of TBC1D8B in this 
process, transferrin endocytosis and recycling assays were performed in affected 
individuals’ podocytes and fibroblasts harbouring p.Phe291Ser and p.Gln246His variants, 
respectively. Transferrin is a widely used marker for both clathrin-
mediated internalization and recycling pathways in most cell types [204]. After 
internalization from the plasma membrane and before being recycled back to cell surface, 
transferrin and its receptor accumulate in the PNRC [205],[206]. Here, a delay in 
transferrin uptake in affected individuals’ cells compared to control subjects was 
detected. However, endocytosis was significantly slower in mutant fibroblasts and 
podocytes. In addition, analysis of transferrin recycling revealed a significant decrease of 
normalized fluorescence intensity 45 min after transferrin loading in WT podocytes, 
whereas it was maintained in the PNRC in affected individuals’ cells. Altogether, these 
results strongly suggest that both endocytosis and vesicular recycling are altered in 
affected podocytes. 
In cells, PNRC dynamics and recycling are mostly regulated by Rab11. We then 
hypothesized that TBC1D8B might be a crucial GAP for Rab11 that displays at least two 
isoforms (Rab11a and Rab11b) both present in mouse podocytes [206], [207]. By co-
immunoprecipitation experiments in HEK293T cells, we showed that the Rab-binding 
domain (RBD) of TBC1D8B was able to interact with a dominant active, GTP-bound, 




interaction between endogenous TBC1D8B and DA-Rab11b. In addition, we showed that 
DA-Rab11b and TBC1D8B Rab-binding domain colocalized at the PNRC when co-expressed 
in podocytes, but interestingly, the widespread Rab11b signal in WT cells shifted to a very 
restricted localization to the PNRC in mutant podocytes, which suggests that GTP-bound 
Rab11b is trapped in the PNRC in cells from affected individuals. Altogether, these data 
strongly suggest that TBC1D8B is a specific Rab11b-GTPase activating protein. 
 
Numerous proteins are subject to Rab11-dependent recycling in various cell types, 
especially in neurons [208]. However, although it has been shown that some proteins are 
recycled in a Rab11b-dependent manner, only a few studies explored the role of Rab11b 
on vesicular trafficking [209]. In 2016, Grimsey et al. reported the crucial role of Rab11b 
GTP hydrolysis for the initiation of transferrin recycling from the PNRC to the plasma 
membrane [210]. In podocytes SD integrity is of utmost importance and several SD 
proteins are subjected to endocytic and recycling events to maintain their regulation 
[211]. Very recently, mutations in GAPVD1, a Rab5 effector showed to be involved 
in nephrin regulation at the SD, were reported as disease causing [200]. In our study, we 
did not find any interaction between TBC1D8B and Rab5, suggesting that Rab5 is not a 
target of TBC1D8B. Thus, our results highly suggest that some podocyte-specific proteins 
could specifically use the Rab11b-dependent recycling pathway, as it has been shown for 
some SD proteins and the use of the Rab5-dependent pathway [200]. By this means, 
alterations in Rab11b activation would lead to SD dysregulation, implying that not only 
endocytosis but also recycling are of fundamental importance for SD integrity. Indeed, it 
is likely that mutations in TBC1D8B lead to strong defect in recycling processes in 
podocytes, which could also induce a defect in transferrin uptake linked to decrease 
number of receptors at the plasma membrane at steady state. 
 
Altogether, our results confirmed that mutations in TBC1D8B gene are involved in the 
development of early SRNS in rare affected individuals. We show herein that vesicular 
trafficking plays a fundamental role in podocyte disease, especially in SRNS, through a 
Rab11-dependent recycling process. Recent discoveries in monogenic SRNS and especially 
in SD regulation during disease through endocytic and recycling pathways would certainly 





Chapter 7: CDCP1 is a Novel Binding Partner of Podocin  
7.1 Introduction 
Although podocin has been the subject of much research, the majority of this has been 
done in transfected human embryonic kidney cells (HEK293) and not in podocin’s bona 
fide cell type, the kidney podocyte. As a further step in understanding podocin biology, 
identification of novel binding partners of podocin in podocytes is required to provide 
new insights into the functions of this protein. As mentioned in Chapter 1, podocin plays 
an important role in establishing a lipid-enriched signalling platform by which numerous 
proteins, such as nephrin and TRPC6, are recruited to the slit diaphragm of podocytes 
[212]. It is currently well understood that podocin acts as a scaffold for the recruitment of 
proteins for correct function of the slit diaphragm complex [213]. Although, it is known 
that the unique structure of this multiprotein complex requires a tight regulation of the 
local protein environment, the exact make up of this complex in health and disease is still 
unclear [214]. Therefore, there is a need for identification of novel proteins interacting 
with podocin that could provide more information about its cellular roles and functions. 
In the current study, wild-type podocin was subjected to a targeted proteomic approach 
in order to identify and characterize novel interacting partners. This system provides an 
accurate mass data that identifies and quantifies the proteins, even those of low 
abundance, within complex mixtures in a single experiment [215]. An analysis of 
proteomic data revealed several proteins linked to major pathways associated with 
variety of cellular processes, such as intracellular transport and autophagy. CD2AP, a 
known podocin interactor, was identified, therefore validating the screen. The 
interactome also contained several signalling molecules and receptors. To further validate 
the interactome, it was compared to the recently performed proteomic screen of FLAG-
tagged podocin expressed in podocytes [214]. Here, a significant number of proteins and 
receptors, such as podocin, ephrin type-A receptor 2 and receptor-type tyrosine-protein 
phosphatase F, were found to match.  
Here, most of the work is focused on the characterization of the processes that lead to 
the adhesive defect of the mutant podocytes derived from the patients bearing the R138Q 
mutation. Cell migration is a dynamic process of leading edge protrusion, focal adhesion 
turnover and generation of retraction/detachment forces that is not only involved in a 




as cancer as seen with metastasis [216], [217]. The major players during these events are 
the integrin family of cell adhesion receptors, which can control cellular migration as well 
as other intracellular functions via their interaction with a variety of cytoskeletal and 
signaling molecules [218]. Indeed, interaction between focal adhesion kinase (FAK) and 
Src family kinases (SFKs) is the main driving force of cellular migration and attachment 
[219].  
7.2 Methods 
7.2.1 CDCP1 antibody uptake 
CDCP1 antibody (ThermoFisher, #PA5-17245) uptake was performed as previously 
described in section 6.2.3. The same protocol was followed as for the transferrin assay.  
7.3 Results 
7.3.1  CDCP1 is a novel podocin interactor 
Figure 7.2A shows the proteomics data from 2 independent experiments using two 
different extraction buffers demonstrating that CUB domain containing protein 1 (CDCP1) 
was identified as an interacting protein for podocin. Western Blot of a GFP TRAP with 
Podocin GFP and CDCP1 confirms the proteomic screen (Figure 7.2B). Next, 
immunofluorescence studies were performed to show colocalization between podocin 
GFP (steady state) and trafficking CDCP1 (antibody uptake for 20 mins). We also show TIRF 
images of FAKpY397 – a marker for focal adhesions and CDCP1 in WT cells. The CDCP1 
lines up along F-actin filaments and FAK around the periphery of the cell with a few 
filaments in the centre (Figure 7.2C). The CDCP1, F-actin and FAKpY397 in the PM cells is 
localised throughout the cell, implying that focal adhesion dynamics are dysregulated in 
PM cells (Figure 7.2C). TIRF images also display an increased FAKpY397 expression in PM 
































Figure 7.1 CDCP1 and Podocin. (A) Results from proteomics using different 
immunoprecipitation buffers from WT Human ciPodocytes stably expressing WT podocin 
GFP differentiated for 10 days. (B) Co-immunoprecipitation between over expressed WT 
podocin GFP and endogenous CDCP1. (C) Co-localisation studies between steady state WT 
podocin GFP and CDCP1 after 20 minutes antibody uptake in differentiated Human ciPods. 






7.3.2 Western Blotting analysis of FAK and CDCP1 protein levels 
To further confirm immunofluorescence studies, western blotting was performed to look 
at FAK and CDCP1 protein levels in human podocytes derived either form a healthy 
individual (WT) or a patient with the R138Q mutation (PM). Similar to IF, there is a 
significant increase in FAK y397 phosphorylation in PM cells, while an increase in FAK y925 
phosphorylation was also observed in these cells (Figure 7.2A). There was no change in 
CDCP1 expression detected between the cell lines, however, the 70 kDa cleaved form of 



















Figure 7.2 Western Blotting analysis. (A) Relative protein levels of FAK, FAKpY925 and 
FAKpY397 in differentiated WT and PM cells. Results from three independent 
experiments. Two-tailed T-test, * P≤0.05. (B) Relative protein levels of CDCP1 in 




7.3.3 CDCP1 interacts with total beta integrin 1  
Literature reports suggest that CDCP1 and beta integrin 1 interact, and that CDCP1 has a 
regulatory effect on FA turnover/activity. This interaction is observed both in WT and PM 
cells, but the interaction is much reduced/abolished in the PM cells, and is rescued in PM 
cells expressing WT Podocin GFP (Figure 7.3A). There’s no difference in levels of active 
beta integrin 1, and active beta integrin 1 does not interact with full length or cleaved 




Figure 7.3 CDCP1 and beta integrin 1. (A) A representative western blot of co-
immunoprecipitation between CDCP1 and total -integrin 1 in differentiated PM, PM+WT 
podocin GFP and WT Human ciPods. (B) Co-immunoprecipitation of active -integrin1 
with full length and cleaved CDCP1. 
7.3.4 Functional rescue 
Since podocin is known to associate with lipid rafts, a flotation gradient centrifugation 
was performed to see whether CDCP1 is present in these lipid microdomain, and how its 
recruitment is affected by the R138Q mutation. Flotillin-1 was used as a lipid raft marker. 




disrupted in PM cells, however, is rescued in the presence of WT podocin GFP (Figure 
7.4A). This experiment was done by Dr. Ruth Rollason (University of Bristol). Importantly, 
the introduction of WT podocin GFP to the PM cells resulted in the rescue of the 




















Figure 7.4 Rescue experiments. (A) Representative western blots of DRMs extraction 
from undifferentiated and differentiated WT, PM and PM+WT podocin GFP Human 
ciPods. Results were analysed by ANOVA and Bonferonni’s multiple comparison test, 
significance *, n=4. (B) Adhesion assay of differentiated WT, PM and PM+WT podocin GFP 
Human cipods. Results were analysed by ANOVA and Bonferonni’s multiple comparison 







One of the novel proteins that came up on the proteomic screen was CUB domain-
containing protein 1 (CDCP1), and was shown to interact with WT podocin (Figure 7.1A 
and B). Human tumor associated gene, CDCP1, was first identified and mapped to a 
chromosome 3p21-p23 from human colorectal cancer cells, due to its elevated expression 
in these cell lines in comparison with normal tissue [220]. CDCP1 is an integral membrane 
glycoprotein located on the cell membrane that has been previously reported to play a 
role in cancer metastasis [221]. Importantly, in animal models of cancer, such as prostrate, 
melanoma and lung adenocarcinoma, CDCP1 has been reported to play a role in 
metastasis progression [222], [223]. CDCP1 is mostly expressed in epithelial linings with 
no expression detected in fibroblasts and other mesenchymal-derived cells [224]. This 
protein was found to regulate cellular migration and adhesion, and it is known that both 
loss of and gain of functions of CDCP1 can ultimately result in the inhibition of migration 
[225]. CDCP1 is a 836 amino acid protein made of a 29 amino acid signal peptide at the N-
terminus, followed by an extracellular domain, a transmembrane domain and a 150 amino 
acid cytoplasmic domain (Figure 7.5) [226]. Furthermore, the extracellular domain 
consists of three CUB (complement protein subcomponents C1r/C1s, urchin embryonic 
growth factor and bone morphogenetic protein 1) domains defined by immunoglobin-like 
folds and that are believed to be required for protein-protein interactions [226]. In 
addition, there are 14 N-glycosylation sites in the extracellular domain [226]. On the other 
hand, the cytoplasmic domain contains five evolutionary conserved tyrosine residues, 
which can be phosphorylated, and two proline-rich regions that are able to act as SH3 





Figure 7.5 Schematic cartoon of human CDCP1. The full length CDCP1 consists of an 
extracellular domain made of three CUB domains containing 14 N-glycosylation sites, a 
transmembrane domain and a 150 amino acids cytoplasmic domain containing tyrosine 
residues. Reproduced from Uekita and Sakai [226].  
The full-length, 135 kDa CDCP1 protein is also known to undergo a specific protease 
cleavage into a smaller 70 kDa cytoplasmic fragment and a 65 kDa protein portion on the 
extracellular part of the membrane [228], [226]. Proteases, such as plasmin and trypsin, 
have been shown to cleave CDCP1, and there is growing evidence to support the fact that 
this cleavage is required for the activity of the protein [223]. It has been demonstrated 
that the CDCP1 cleavage by plasmin-like serine proteases results in a signal transduction 
via a β1 integrin/FAK/PI3K/Akt signalling cascade that induces early stages of metastasis 
development leading to tumor cell invasion [223]. In addition to cleavage, activity of 
CDCP1 is dependent on its phosphorylation state; both full length and cleaved CDCP1 can 
be phosphorylated by Src family kinases (SFKs), such as Src, Fyn and Yes [222], [219]. 
Interestingly, the non-receptor tyrosine kinase focal adhesion kinase (FAK) was recently 
discovered to play a role in processes, such as cell adhesion and migration [229]. In 
particular, FAK is essential for integrin mediated signalling during cell adhesion, where 
integrin binding results in autophosphorylation of FAK at Y397, which, in turn, causes 
conformational changes and further Src phosphorylation of FAK at Y925, Y576/577, Y861 
and Y407 [219]. 
Here, we demonstrate that total beta integrin 1 interacts with CDCP1, when podocin is 
correctly targeted to the plasma membrane (Figure 7.6). However, in the presence of the 
R138Q mutation, this interaction is reduced or diminished, which results in the elevated 
phosphorylation of FAK at Y397 and Y925, the sites associated with Src phosphorylation 
and autophosphorylation [230]. This, in turn, leads to FAs disassembly, which might 
explain the adhesive defect of the mutant cell line. Importantly, the introduction of WT 
podocin GFP resulted in the restoration of the mutant cells function and the recruitment 



















Altogether, it can be proposed that podocin interacts with and traffics CDCP1 to the 
plasma membrane in podocytes and aids its recruitment to the lipid raft microdomains. 
Moreover, the CDCP1-beta integrin 1 interaction only occur in the presence of podocin at 
the plasma membrane and is required for the normal adhesion and motility of podocytes. 
However, further work is required to identify the exact signalling events happening during 
the complex formation. It will be interesting to see if the introduction of WT podocin GFP 





WT cells                                         PM cells 
Figure 7.6 Proposed model of beta integrin 1/CDCP1/podocin complex formed at the 
plasma membrane of human podocytes. The R138Q mutation, results in the mutant 
protein being retained in the ER, resulting in the aberrant formation of the complex and 




Chapter 8: Conclusions and Future Work 
 
The work of this thesis describes a previously unknown molecular mechanism involved in 
the endoplasmic reticulum retention of the R138Q disease-causing mutation of podocin. 
Podocin is a podocyte specific integral membrane protein essential for intact glomerular 
filtration. To date, mutations in podocin represent the commonest form of the genetic 
NS. As described in Chapter 1, the most frequent podocin mutation is the R138Q missense 
mutation, which results in this protein being misfolded and retained in the ER. Therefore, 
a key aim of glomerular research is to discover small molecules that correct this trafficking 
defect. Using our unique conditionally immortalized human podocyte cell lines, derived 
from both wild-type and from patients bearing the R138Q podocin mutation, and various 
in vitro biochemical assays, such as PLA, IF and immunoprecipitation, the current work 
has demonstrated that the R138Q mutant but importantly not wild-type podocin 
associates with the intermediate filament keratin 8. Furthermore, treatment with the in 
silico-selected compound 407 resulted in the rescue of mutant podocin localization back 
to the plasma membrane, and more importantly restored the adhesive defect of mutant 
podocytes and structure of podocin-dependent lipid rafts (Figure 8.1). The same results 
were observed, when an shRNA-based approach was used to target the association 
between keratin 8 and R138Q podocin mutant in human podocytes. In vivo, a podocyte 
specific, doxycycline inducible triple transgenic mouse model of the R140Q mutation (a 
mouse analogue of the human R138Q mutation) was generated to test c407. Four weeks 
treatment with c407 by osmotic mini pumps led to prevention of the proteinuria in those 





Figure 8.1 Proposed model for the mutant protein retention and rescue from the ER. 
The R138Q podocin associates with keratin 8 network, which, in turn, results in its ER 
accumulation and potential proteasomal degradation. However, if this interaction is 
inhibited by the corrector, such as c407, the R138Q podocin mutant can reach the plasma 
membrane and become functional.   
 
Broadly, this work suggests a key role for the keratin 8 network in mutant podocin 
misprocessing and agrees with the previously published studies done by Colas et al., 
where the disruption of the mutant F508del-CFTR and keratin 8 interaction resulted in the 
functional form of the mutant protein at the plasma membrane [130]. Interestingly, 
keratin 8 has also been shown to be involved in alpha-1-antitrypsin (A1AT) secretion 
and/or degradation [231]. A1AT is a ubiquitously expressed inhibitor of inflammatory cells 
that appears to have its main physiological role in the lungs, where it protects them from 
degradation [232]. The Z mutation in alpha-1-antitrypsin (A1AT) represents one of the 
common forms of the genetic A1AT deficiency and also results in the misfolded form of 
protein, which is targeted for proteasomal degradation or for polymerization and 
autophagy [231]. A1AT deficiency is a rare genetic disease that presents as pulmonary 
emphysema, liver cirrhosis and, in rare cases, as the skin disease panniculitis, and is 




with misfolded Z-A1AT, thus preventing it from correct targeting and secretion [231]. 
Based on the above, it will be interesting to investigate the role of keratin 8 in other 
protein misfolding disorders of the ER, such as Gaucher disease. Gaucher disease is an 
autosomal recessive disorder, in which patients present with the deficiency in the β-
glucosidase, a membrane-associated lysosomal enzyme protein [233]. Similar to 
misfolded CFTR and podocin proteins, missense variant β-glucosidase protein is also 
accumulated in the ER and targeted for the proteasomal degradation in the cytosol [234]. 
While the precise effects of the R138Q podocin mutation on podocyte biology are 
incompletely understood, this work provides many potential leads and ideas. Experiments 
have been set up to see, whether the mutant podocin is targeted for proteasomal 
degradation in vitro. In vivo, mouse work has been started to see if a complete rescue of 
proteinuria can be achieved, when c407 is administrated after proteinuria has 
commenced. Further work should help to add new discoveries to what is already known, 
and hopefully start to lead to potential therapies for the disease course.  
8.1 Complication of this work  
Podocytes act as key players in the maintenance of the glomerular filtration barrier and a 
disruption in their function, as in the case of the R138Q mutation, ultimately results in 
glomerular disease, an understanding of the precise molecular mechanisms involved in 
the ER retention of the mutant protein is essential in the understanding of the underlying 
pathogenesis of SRNS. Work carried out in this thesis has developed a novel concept in 
understanding the effects of the R138Q podocin mutation on podocyte biology. It has 
established that the keratin 8 network is involved in the retention of the mutant protein. 
However, the main limitation of this work was that it had not conclusively proved that the 
two proteins interact directly, and this will require purified forms of both proteins for 
interaction studies.  
During this project, PCR based molecular cloning methods were employed to generate 
pET-32(a) wt/R138Q podocin plasmids, which were used for protein purification. An 






Figure 8.2 Schematic diagram showing the steps for PCR based molecular cloning, in 
which Xho I and EcoR I sites are incorporated into the WT and R138Q podocin prior to 
ligation into a pET-32(a) vector. 
 
Unfortunately, multiple attempts to purify both the wild-type and mutant forms of 
podocin were unsuccessful. Integral membrane proteins, such as podocin, are known to 
be difficult to purify. Therefore, a collaboration was established with a drug discovery 
contract research organisation, DomaineX, in order to purify both keratin 8 and podocin 
to investigate their protein-protein interaction. To date, DomaineX have managed to 
obtain affinity purified full length keratin 8 and the portion of the podocin protein 
containing the R138Q missense mutation. Direct interaction between the two partner 
proteins has been demonstrated using a microscale thermophoresis (MST) assay. 
However, due to incorrect folding of purified podocin and hence aggregation, the assay 
has still to be optimised to allow calculation of binding affinity. This work is ongoing, as 
setting up a protein/protein interaction assay will allow for the development of a 






8.2 On-going work  
8.2.1 Development of c407 analogues  
The lead compound in this project, c407 is a small-molecule selected from the National 
Cancer Institute’s Diversity compound database, whose properties were shown to be 
within drug-like properties. The low molecular weight, lipophilicity and polar surface area 
of this compound allow for considerable scope for optimisation. One of the further aims 
of this project is to develop c407 into a series of novel molecules that can inhibit the 
R138Q podocin – keratin 8 association, for the eventual treatment of SRNS. Through the 
collaboration with Domainex, over 40 c407 analogues have so far been acquired or 
synthesized to be tested in a cell adhesion assay. The optimization of analogues 
systemically involves changes to the phosphinate, aromatic, and linker groups, and 
symmetry of the molecule in order to elevate their pharmacokinetical potency and 




Figure 8.3 An example of the optimization protocol obtained from Domainex. The 
diagram shows various phosphinate replacements, alternative linkers and linker lengths, 
along with alternative substituents, such as small alkyl and halogen, and heteroaromatics.  
 
Alongside, a small number of c407 analogues has been obtained from our French 
collaborators (Paris, INSERM) and tested in a robust cell adhesion assay. Mutant 
podocytes derived from a patient with a homozygous R138Q mutation have significantly 
less adhesion than healthy wild-type podocytes, which can be rescued using the small 




minus c407 analogues, and the results obtained so far show that some selected analogues 
are able to (partially) restore the WT-phenotype, while others do not (Figure 8.4). 
 
 
Figure 8.4 Cell adhesion assay of the c407 analogues. Some selected analogues, such as 
112,194,606 and 610, are able to significantly restore the WT-phenotype, while other 
analogues, such as 195, 196 and 609, do not. Results are representative of 3 independent 
experiments; One-way ANOVA analysis P<0.0001. 
 
These results have given significant clues as to how to optimize the c407 compound and 
this work is continuing. Further work will include testing of 20 different c407 related 
compounds generated by Domainex for dose and efficacy. The most suitable analogues 
derived from this test will be chosen and tested in vivo. Experiments will be performed in 
mouse knock-in model of podocin R140Q, using implantable minipumps and oral gavage 
(described in more details below) for effect and dose response. Readouts will be as before 
and include weekly proteinuria measurements, plasma renal profiles and renal 
histology/ultrastructure/immunofluorescence. The eventual aim of this project is to 
identify at least one candidate compound from the lead series, which demonstrates the 
most ideal pharmacokinetic (PK) profile in a mouse model of human R138Q mutation 





8.2.2 Oral gavage of c407 
To further test the efficacy of c407, it is important to determine whether it gets orally 
absorbed; whether it achieves relevant plasma concentration; and how long for does it 
stay in the blood. One of the best ways to answer these questions is to perform the 
administration of the drug directly into the stomach of mice or rats via a technique known 
as oral gavage [235]. This procedure involves the delivery of the compound into the 
stomach using stainless steel bulb tipped gavage needle or a flexible cannula attached to 
a syringe [235]. During this work, 2 mg of c407 was given orally twice a day for 17 days, 
alongside the doxycycline that was administered in the drinking water for the duration of 
the whole experiment. Urine was collected every 4 days, and blood samples were taken 
via facial vein at 4, 6, 8 hours after the c407 delivery for pharmacokinetic studies (PK) 
(Figure 8.5a). Blood samples were analysed by Domainex, and the mean plasma 
concentrations of c407 was shown to remain above 340ng/mL (>1µM) at 6 hours (Figure 
8.5b). C407 was shown to be orally bioavailable following oral gavage administration, and 
the compound appeared to be well-tolerated during in vivo studies (clinical and 
behavioural observations Figure 8.5c). Moreover, c407 delivered orally prevented the 
development of proteinuria in mouse knock-in model of podocin R140Q starting from day 
4 (Figure 8.5d). Orally given c407 also prevented the elevation of blood cholesterol, urea 
and creatinine (Figure 8.5e). Although phosphinate present in c407 is a relatively 
uncommon functional group in the pharmacopeia, the properties of c407 present no 
obvious liabilities, proving its oral bioavailability. This is supported by the fact that some 
drugs containing phosphinate groups, such as Fosinopril, are currently being used in clinic. 
Fosinopril is an approved phosphinate-containing drug that is used in patients with heart 










Figure 8.5 c407 administration by oral gavage. Blood samples were collected via facial 
vein (a) and (b) analysed for the mean plasma concentration of c407. (c) Clinical and 
behaviour signs were observed to be normal in c407 treated animals, while mice that 
were given saline had a scruffy appearance. (d) C407 oral administration prevented the 




p=0.0054; p=0.0072; p=0.0158. (e) Normal plasma renal profiles were observed with c407 
treatment. Two-tailed T-test, p=0.0012.  
 
8.3 Summary of main conclusions  
Multiple conclusions have been drawn from data obtained over the course of this work. 
The implications of many of these are extremely important, and they represent future 
leads and directions for the project to develop a novel treatment for Nephrotic Syndrome. 
The following table summarizes the findings addressed in each chapter (Table 8.1).  
 
Chapter Main Findings 
Chapter 4 
 
Creation of a conditional knock-in 
mouse model of the R140Q mutation 
• a podocyte specific, doxycycline 
inducible triple transgenic mouse 
model of the R140Q mutation (a 
mouse analogue of the human 
R138Q mutation) was generated 
• Doxycycline induction of a 
hemizygous state in the 
NPHS2flox/R140Q mice led to severe 
proteinuria detectable within few 
days, which peaked to a maximum 
at 2-4 weeks and was maintained at 
week 12 
• Animals presented with 
hypoalbuminemia, 
hypercholesterolemia, uremia and 
abnormally high plasma creatinine 
levels at the point of sacrifice 
• Loss of podocin and nephrin 
expression associated with the loss 
of podocytes was observed  
• Proteinuric animals develop global 
glomerulosclerosis, podocyte foot 
process effacement and global 






Disruption of cytokeratin-8 
interaction with R138Q podocin 
corrects its functional defect both in 
vitro and in vivo 
• R138Q podocin mutant is retained 
in the ER and not able to associate 
with lipid raft microdomains 
• Keratin 8 preferably associates with 
the R138Q mutant over its wild-
type counterpart 
• Silencing of keratin 8 resulted in the 
rescue of mutant protein 
localization and function 
• C407 treatment rescued both the 
mutant protein localization back to 
the plasma membrane and 
adhesive defect of the mutant cells  
• In vivo treatment with c407 
prevented the development of 
proteinuria with normal renal 
plasma levels and histology as seen 
on PAS and EM  
Chapter 6 
 
TBC1D8B loss-of-function mutations 
lead to X-linked Nephrotic Syndrome 
via defective trafficking pathways  
• New gene mutated in SRNS was 
identified 
• TBC1D8B is present both in 
glomerular podocytes and in 
mature kidney 
• p.Phe291Ser mutation resulted in 
an increased adhesion and a 
decreased migration of human 
mutant podocytes 
• Foot process effacement and 
disappearance of slit diaphragms 
were seen in tbc1d8b−/− KO fish 
• Mutant cells displayed a delay in 
recycling processes  
Chapter 7 
 
CDCP1 is a novel interacting partner 
of podocin  
• CDCP1 interacts with WT podocin 
• CDCP1 interacts with beta integrin 
1 in WT cells 
• Introduction of the WT podocin 
GFP into the PM cells rescues the 
adhesive defect 
• CDCP1 is recruited to the lipid raft 
microdomains 
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Cell culture and cell extraction reagents 
Sigma Aldrich, Poole, UK: 
RPMI Media 1640 (#R8758) 
ITS liquid media supplement (#I3146) 
Penicillin-Streptomycin (#P4333) 
Foetal Bovine Serum (FBS) (#F7524) 
DMEM x1 + Glutamax 
DMSO (#D8418) 
Trypsin-EDTA (#T3924) 
Protease inhibitor cocktail (#P8340) 
Gel electrophoresis and western blotting reagents 
 
Severn Biotech Ltd, Worcester, UK 
Acrylamide/Bis-acrylamide solution (#20-2100-05) 
Millipore, MA, USA 
PVDF Immobilon-P Transfer Membrane (#IPVH00010) 
Sigma Aldrich, Poole, UK 
Bovine Serum Albumin (BSA) (A9647) 
Thermo Scientific, IL, USA 
SuperSignal west femto maximum sensitivity substrate (#34096) 
Solutions: 





1 x Phosphate Buffered Saline (PBS) (pH 7.4): 
Reagent Concentration 
NaCl 137 mM 
Na2HPO4 10 mM 
KCl 2.7 mM 
KH2PO4 2 mM 
 
Podocyte culture medium (500ml RPMI 1640) containing: 
Reagent Amount 
FBS 50ml (10%) 
ITS 5ml 
Pen Strep  5ml 
 
HEK culture medium (500ml DMEM x1 + Glutamax) containing: 
Reagent Amount 
FBS 50ml (10%) 
 
Cell culture medium for cryoprecipitation (10 ml): 
Reagent Amount 
Cell culture medium 5 ml 
FBS 4 ml 
DMSO (Sigma #D8418) 1 ml 
 
TNE Buffer pH 7.4 (wash buffer): 
Reagent Concentration 
Tris base (Sigma #T6791) 50 mM 
NaCl 150 mM 
EDTA 0.5 mM 
 






NP40 (Sigma #I8896) 2% 
Glycerol 10% 
Protease inhibitor cocktail 100l 
 
Solutions used in gel electrophoresis and western blotting 
Tris 0.5M pH 6.8 reagents list: 
Reagent Amount 
Tris base (Sigma #T6791) 24.23g 
dH2O  250ml 
Total 250ml 
 
Tris 3M pH 8.8 reagents list: 
Reagent Amount 
Tris base 90.85g 




 STACK RESOLVING 
 Standard (4%) 10% 12.5% 15% 
30% Bis-Acrylamide (Severn 
Western, UK #20-2100-05) 
1.25ml 6.7ml 8.4ml 10ml 
Tris (0.5M) pH 6.8 2.5ml - - - 
3M Tris buffer - 2.5ml 2.5ml 2.5ml 
10% SDS 100l 200l 200l 200l 
APS (Sigma #A3678) 30mg/ml 0.5ml 1ml 1ml 1ml 
TEMED (Sigma #T9281) 5l 10l 10l 10l 
dH2O 5.65ml 9.6ml 7.9ml 6.3ml 
 




Reagent Concentration  
Tris base 0.25 M 
Glycine (Sigma #G8898) 1.92 M 
SDS (Sigma #L3771) 1% (w/v) 
 
Transfer buffer (10x) reagents list: 
Reagent Concentration  
Tris base 0.25 M 
Glycine 1.92 M 
 
TBS-T (10x) pH 7.6 reagents list:  
Reagent Concentration 
Tris base 200 mM 
NaCl 1.4 M 
Tween-20  1 % (v/v) 
 
BSA (5%) reagents list: 
Reagent Amount 
BSA 12.5g 
TBS-T (1x) 250ml 
Total 250ml 
 
BSA (3%) reagents list: 
Reagent Amount 
BSA 7.5g 
TBS-T (1x) 250ml 
Total 250ml 
 
SDS-Sample buffer (4x) reagents list: 
Reagent Concentration 
SDS  8 % 
Tris-HCl pH 6.8 240 mM 
bromophenol blue 0.04 % 
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